Peter Valent

Q: What Schools Are Affiliated With Peter Valent

Peter Valent is affiliated with the following schools: Medical University of Vienna, Technical University in Zvolen, University of Minnesota, Slovak University of Technology in Bratislava, University of Vienna

Peter Valent's AcademicInfluence.com Rankings

Peter Valent

Medical

#736

World Rank

#971

Historical Rank

Hematology

World Rank

Historical Rank

medical Degrees

Download Badge

Medical

Peter Valent's Degrees

Doctorate Medicine Medical University of Vienna
PhD Hematology Medical University of Vienna

Why Is Peter Valent Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Peter Valent is an Austrian hematologist and stem cell researcher. Since 1990 he leads a research group at the Medical University of Vienna. From 2002 he coordinates the European Competence Network on Mastocytosis and since 2008 he is Scientific Director of the Ludwig Boltzmann Institute for Hematology and Oncology of the Ludwig Boltzmann Society in Austria.

(See a Problem?)

Peter Valent's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised international prognostic scoring system for myelodysplastic syndromes. (2012) (2285)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia (2011) (1699)
Diagnostic criteria and classification of mastocytosis: a consensus proposal. (2001) (1010)
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. (2007) (750)
Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria (2007) (695)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. (2007) (650)
Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. (1991) (630)
Cancer stem cell definitions and terminology: the devil is in the details (2012) (619)
Profilins constitute a novel family of functional plant pan-allergens (1992) (608)
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. (2012) (587)
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. (2012) (567)
Definitions, Criteria and Global Classification of Mast Cell Disorders with Special Reference to Mast Cell Activation Syndromes: A Consensus Proposal (2011) (479)
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. (2007) (477)
Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. (1992) (461)
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. (2017) (439)
Transcriptional plasticity promotes primary and acquired resistance to BET inhibition (2015) (402)
Simvastatin Reduces Expression of Cytokines Interleukin-6, Interleukin-8, and Monocyte Chemoattractant Protein-1 in Circulating Monocytes From Hypercholesterolemic Patients (2002) (386)
Vaccination with genetically engineered allergens prevents progression of allergic disease (2004) (362)
MDR1 gene expression and treatment outcome in acute myeloid leukemia. (1991) (353)
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. (2016) (308)
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. (2002) (291)
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib (2007) (275)
Allergen‐specific immunotherapy with a monophosphoryl lipid A‐adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy‐induced blocking antibodies (2003) (270)
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML (2011) (269)
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells (2009) (263)
Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. (2016) (258)
Mast cell activation syndrome: Proposed diagnostic criteria. (2010) (257)
Identification of common allergenic structures in hazel pollen and hazelnuts: a possible explanation for sensitivity to hazelnuts in patients allergic to tree pollen. (1992) (257)
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. (2015) (246)
Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. (1994) (246)
Stat5 tetramer formation is associated with leukemogenesis. (2005) (245)
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. (2005) (245)
Recombinant Carp Parvalbumin, the Major Cross-Reactive Fish Allergen: A Tool for Diagnosis and Therapy of Fish Allergy1 (2002) (240)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2019) (237)
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. (2006) (230)
The Basophil-Specific Ectoenzyme E-NPP3 (CD203c) as a Marker for Cell Activation and Allergy Diagnosis (2004) (229)
Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. (1997) (223)
Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes. (1989) (218)
Interleukin-3 is a differentiation factor for human basophils. (1989) (217)
Mastocytosis: State of the Art (2007) (216)
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group (2012) (215)
Anemia at older age: etiologies, clinical implications, and management. (2018) (215)
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1 (2017) (213)
Comprehensive mutational profiling in advanced systemic mastocytosis. (2013) (208)
Interleukin 3 activates human blood basophils via high-affinity binding sites. (1989) (207)
Diagnostic value of immunostaining for tryptase in patients with mastocytosis. (1998) (205)
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes (2009) (205)
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. (2003) (202)
Cell surface structures on human basophils and mast cells: biochemical and functional characterization. (1992) (202)
Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. (2001) (199)
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. (2011) (197)
Diagnosis and treatment of systemic mastocytosis: state of the art (2003) (195)
Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. (1995) (194)
Mastocytosis: Pathology, genetics, and current options for therapy (2005) (194)
KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis (2015) (192)
The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. (1999) (190)
Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease (2002) (189)
Response of L-929 Fibroblasts, Human Gingival Fibroblasts, and Human Tissue Mast Cells to Various Metal Cations (1995) (186)
Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. (2001) (185)
Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. (1991) (185)
Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. (2002) (181)
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. (2017) (181)
Mast Cells, Mastocytosis, and Related Disorders. (2015) (181)
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. (2014) (172)
The in vivo effects of recombinant human interleukin-3: demonstration of basophil differentiation factor, histamine-producing activity, and priming of GM-CSF-responsive progenitors in nonhuman primates. (1989) (165)
Identification of Der p 23, a Peritrophin-like Protein, as a New Major Dermatophagoides pteronyssinus Allergen Associated with the Peritrophic Matrix of Mite Fecal Pellets (2013) (163)
A Recombinant Hypoallergenic Parvalbumin Mutant for Immunotherapy of IgE-Mediated Fish Allergy1 (2007) (162)
Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy (1999) (159)
Purification, biochemical, and immunological characterisation of a major food allergen: different immunoglobulin E recognition of the apo- and calcium-bound forms of carp parvalbumin (2000) (159)
Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge (2004) (159)
Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. (2004) (157)
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS) (2005) (156)
Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. (2004) (155)
Molecular and Immunological Characterization of Arginine Kinase from the Indianmeal Moth, Plodia interpunctella, a Novel Cross-Reactive Invertebrate Pan-Allergen1 (2001) (155)
Detection of molecular targets on the surface of CD34+/CD38− stem cells in various myeloid malignancies (2006) (154)
Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients (2003) (152)
CD25 Indicates the Neoplastic Phenotype of Mast Cells: A Novel Immunohistochemical Marker for the Diagnosis of Systemic Mastocytosis (SM) in Routinely Processed Bone Marrow Biopsy Specimens (2004) (151)
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. (2012) (148)
Severe peripheral arterial disease during nilotinib therapy. (2011) (148)
cDNA cloning of a major allergen from timothy grass (Phleum pratense) pollen; characterization of the recombinant Phl pV allergen. (1993) (147)
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis (2016) (145)
Expression of the target receptor CD33 in CD34+/CD38−/CD123+ AML stem cells (2007) (145)
The human cardiac mast cell: localization, isolation, phenotype, and functional characterization. (1994) (144)
Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis (2014) (144)
Mutation analysis of C‐KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis (2001) (141)
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions (2017) (141)
Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes (1996) (140)
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field (2012) (140)
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML) (2012) (139)
C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. (2002) (139)
The basophil activation marker defined by antibody 97A6 is identical to the ectonucleotide pyrophosphatase/phosphodiesterase 3. (2001) (139)
Monocytes do not make mast cells when cultured in the presence of SCF. Characterization of the circulating mast cell progenitor as a c-kit+, CD34+, Ly-, CD14-, CD17-, colony-forming cell. (1993) (138)
Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation (2005) (138)
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. (2011) (138)
Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. (2007) (137)
Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD) (2010) (136)
Kit and c-kit Mutations in Mastocytosis: A Short Overview with Special Reference to Novel Molecular and Diagnostic Concepts (2002) (135)
Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer (2018) (135)
Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. (2004) (135)
Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients (1998) (135)
Immunoglobulin E response to human proteins in atopic patients. (1996) (135)
Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. (2001) (134)
Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives (2010) (133)
Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1 (2001) (133)
Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. (1998) (133)
Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination (2001) (130)
Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis (2011) (127)
Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. (2001) (126)
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis (2011) (125)
Biology, classification and treatment of human mastocytosis. (1996) (123)
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. (2014) (123)
Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). (2008) (122)
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. (2018) (122)
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both (2016) (121)
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q (2011) (121)
Time-dependent changes in mortality and transformation risk in MDS. (2016) (120)
Further characterization of surface membrane structures expressed on human basophils and mast cells. (1990) (120)
IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. (1991) (120)
Diagnostic and Subdiagnostic Accumulation of Mast Cells in the Bone Marrow of Patients with Anaphylaxis: Monoclonal Mast Cell Activation Syndrome (2006) (119)
Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. (2019) (118)
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS (2014) (116)
Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. (1998) (115)
PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas (2012) (114)
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study (2012) (114)
Calcium‐dependent immunoglobulin E recognition of the apo‐ and calcium‐bound form of a cross‐reactive two EF‐hand timothy grass pollen allergen, Phl p 7 (1999) (113)
Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. (2010) (113)
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. (2013) (113)
The riddle of the mast cell: kit(CD117)-ligand as the missing link? (1994) (113)
Immunization with purified natural and recombinant allergens induces mouse IgG1 antibodies that recognize similar epitopes as human IgE and inhibit the human IgE-allergen interaction and allergen-induced basophil degranulation. (1998) (112)
Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. (2008) (112)
Current European flood-rich period exceptional compared with past 500 years (2020) (111)
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy (2015) (111)
Immunologic characterization of purified recombinant timothy grass pollen (Phleum pratense) allergens (Phl p 1, Phl p2, Phl p 5). (1996) (111)
How I treat patients with advanced systemic mastocytosis. (2010) (110)
Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event (2014) (110)
Purification and characterization of recombinant Bet v I, the major birch pollen allergen. Immunological equivalence to natural Bet v I. (1993) (110)
Interleukin 4 promotes expression of mast cell ICAM-1 antigen. (1991) (110)
Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. (1998) (110)
Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience (2011) (109)
A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis (2002) (109)
Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. (2011) (109)
Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM) (2015) (108)
Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. (1994) (107)
Identification of common allergenic structures in mugwort and ragweed pollen. (1998) (106)
Mast cell activation syndromes: definition and classification (2013) (106)
The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. (2014) (106)
Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. (2005) (106)
Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review (2008) (106)
Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily (2009) (105)
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study (2017) (105)
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. (2012) (105)
Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). (2001) (104)
Molecular characterization of dog albumin as a cross-reactive allergen. (1994) (103)
Clinical and Biologic Diversity of Leukemias Occurring in Patients with Mastocytosis (2000) (103)
Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy (2016) (100)
Failure to detect IL-3-binding sites on human mast cells. (1990) (100)
The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells. (1997) (96)
Recombinant human interleukin 6 is a potent inducer of the acute phase response and elevates the blood platelets in nonhuman primates. (1991) (95)
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site (2017) (95)
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. (2005) (95)
The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. (1999) (95)
Gastro‐duodenal digestion products of the major peanut allergen Ara h 1 retain an allergenic potential (2006) (94)
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. (2010) (94)
Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. (1994) (93)
Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates--synergism with recombinant human granulocyte/macrophage colony-stimulating factor. (1990) (93)
Variable expression of activation‐linked surface antigens on human mast cells in health and disease (2001) (93)
Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. (1990) (93)
A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. (2011) (92)
Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia (2000) (91)
Non‐anaphylactic surface‐exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination (2004) (91)
Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. (1994) (90)
Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. (2008) (90)
Der p 11 is a major allergen for house dust mite-allergic patients suffering from atopic dermatitis. (2015) (89)
Autoimmune thrombocytopenia in non-Hodgkin’s lymphomas (2008) (89)
A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. (2005) (89)
Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. (2007) (89)
Pharmacologic inhibition of STAT5 in acute myeloid leukemia (2018) (89)
The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. (2002) (88)
Formation of Disulfide Bonds and Homodimers of the Major Cat Allergen Fel d 1 Equivalent to the Natural Allergen by Expression in Escherichia coli* (2003) (88)
Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. (2016) (86)
B cell epitopes of the major timothy grass pollen allergen, Phl p 1, revealed by gene fragmentation as candidates for immunotherapy (1999) (84)
Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies. (1998) (84)
Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy. (2012) (83)
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? (2015) (83)
A Combination Vaccine for Allergy and Rhinovirus Infections Based on Rhinovirus-Derived Surface Protein VP1 and a Nonallergenic Peptide of the Major Timothy Grass Pollen Allergen Phl p 11 (2009) (83)
Diagnostic criteria and classification of mastocytosis in 2014. (2014) (83)
Characterization of Der p 21, a new important allergen derived from the gut of house dust mites * (2008) (83)
Molecular, immunological, and structural characterization of Phl p 6, a major allergen and P-particle-associated protein from Timothy grass (Phleum pratense) pollen. (1999) (82)
Vasoactive intestinal peptide receptor scintigraphy. (1995) (82)
CD44‐positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2) (2007) (82)
Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. (2017) (81)
Molecular and immunological characterization of a novel timothy grass (Phleum pratense) pollen allergen, Phl p 11 (2002) (80)
Antigens Drive Memory IgE Responses in Human Allergy via the Nasal Mucosa (2006) (80)
The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease (2014) (80)
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. (2014) (80)
Detection of Novel CD Antigens on the Surface of Human Mast Cells and Basophils (2002) (79)
Molecular and Functional Characterization of the Urokinase Receptor on Human Mast Cells* (1997) (79)
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT (2007) (79)
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. (2009) (78)
Pathogenesis, clinical features, and treatment advances in mastocytosis. (2006) (78)
Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions (2019) (78)
Indolent Systemic Mastocytosis with Elevated Serum Tryptase, Absence of Skin Lesions, and Recurrent Severe Anaphylactoid Episodes (2005) (77)
Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE‐binding capacity: candidates for grass pollen‐specific immunotherapy (2002) (77)
Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens1 (2008) (77)
Spectrum of Associated Clonal Hematologic Non-Mast Cell Lineage Disorders Occurring in Patients with Systemic Mastocytosis (2002) (76)
Mapping of Conformational IgE Epitopes with Peptide-Specific Monoclonal Antibodies Reveals Simultaneous Binding of Different IgE Antibodies to a Surface Patch on the Major Birch Pollen Allergen, Bet v 1 (2011) (76)
Neoplastic stem cells: A novel therapeutic target in clinical oncology (2006) (76)
A Human Monoclonal IgE Antibody Defines a Highly Allergenic Fragment of the Major Timothy Grass Pollen Allergen, Phl p 5: Molecular, Immunological, and Structural Characterization of the Epitope-Containing Domain1 (2000) (75)
Evaluation of Close-Range Photogrammetry Image Collection Methods for Estimating Tree Diameters (2018) (75)
Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. (2009) (75)
Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology (2009) (75)
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. (2011) (75)
The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. (2008) (75)
Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition. (1998) (75)
Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions (2009) (75)
Hom s 4, an IgE-Reactive Autoantigen Belonging to a New Subfamily of Calcium-Binding Proteins, Can Induce Th Cell Type 1-Mediated Autoreactivity1 (2005) (74)
Conversion of grass pollen allergen‐specific human IgE into a protective IgG1 antibody (2002) (74)
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. (2010) (74)
The complement component C5a induces the expression of plasminogen activator inhibitor‐1 in human macrophages via NF‐κB activation (2006) (74)
Serum Tryptase Measurements in Patients with Myelodysplastic Syndromes (2002) (72)
Induction of specific histamine release from basophils with purified natural and recombinant birch pollen allergens. (1993) (72)
In vivo synergism of recombinant human interleukin-3 and recombinant human interleukin-6 on thrombopoiesis in primates. (1992) (71)
Midostaurin (PKC412) inhibits immunoglobulin E‐dependent activation and mediator release in human blood basophils and mast cells (2009) (71)
Cigarette smoke facilitates allergen penetration across respiratory epithelium (2009) (71)
Adapting forest management to climate change in Europe: Linking perceptions to adaptive responses (2018) (70)
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells (2010) (70)
Characterization of 123I‐vascular endothelial growth factor–binding sites expressed on human tumour cells: Possible implication for tumour scintigraphy (2001) (69)
Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. (2003) (69)
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia (2012) (69)
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. (2007) (69)
Individual Hymenoptera Venom Compounds Induce Upregulation of the Basophil Activation Marker Ectonucleotide Pyrophosphatase/Phosphodiesterase 3 (CD203c) in Sensitized Patients (2002) (68)
Hymenoptera-Venom-Induced Upregulation of the Basophil Activation Marker Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 3 in Sensitized Individuals (2001) (68)
Histopathological and Immunohistochemical Aspects of Mastocytosis (2002) (67)
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group (2012) (67)
The phenotype of human eosinophils, basophils, and mast cells. (1994) (66)
Evaluation of antileukaemic effects of rapamycin in patients with imatinib‐resistant chronic myeloid leukaemia (2007) (66)
Tumor necrosis factor α and interleukin-1β mRNA expression in HMC-1 cells : differential regulation of gene product expression by recombinant interleukin-4 (1993) (66)
NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells (2016) (65)
Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. (2010) (65)
Current treatment options in patients with mastocytosis: status in 2015 and future perspectives (2015) (65)
Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. (2002) (64)
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome (2019) (64)
Emerging stem cell concepts for imatinib‐resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease (2008) (64)
The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm (2017) (64)
A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection. (2014) (64)
Generation of an Allergy Vaccine by Disruption of the Three-Dimensional Structure of the Cross-Reactive Calcium-Binding Allergen, Phl p 71 (2004) (63)
Acute myeloid leukaemia with t(8;21) associated with “occult” mastocytosis. Report of an unusual case and review of the literature (2004) (63)
Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. (2016) (63)
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. (2009) (63)
Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity. (2006) (63)
Conversion of Der p 23, a New Major House Dust Mite Allergen, into a Hypoallergenic Vaccine (2014) (63)
Recent Advances in Mastocytosis Research (1999) (63)
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth‐inhibitory and VEGF‐suppressive effects of rapamycin in leukemic cells (2005) (63)
Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. (2007) (62)
Severe Life-Threatening or Disabling Anaphylaxis in Patients with Systemic Mastocytosis: A Single-Center Experience (2011) (62)
Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. (2000) (62)
Carrier‐bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy (2012) (62)
A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreS–Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 Phenotype (2013) (62)
Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. (2020) (62)
Molecular Aspects of Allergens and Allergy. (2018) (62)
The human basophil. (1990) (61)
Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts (2020) (61)
Expression and prognostic significance of different mRNA 5′‐end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration (2008) (61)
Specific activation of human mast cells by the ligand for c-kit: comparison between lung, uterus and heart mast cells. (1993) (60)
Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. (2013) (60)
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis (2016) (60)
Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms (2011) (60)
Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. (1998) (60)
Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. (2001) (60)
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells (2017) (59)
The growth and differentiation of mast cells. (1991) (59)
Increase and redistribution of cardiac mast cells in auricular thrombosis. Possible role of kit ligand. (1995) (59)
New Aspects in Thrombosis Research: Possible Role of Mast Cells as Profibrinolytic and Antithrombotic Cells (2002) (59)
Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. (2008) (58)
ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications (2018) (58)
CD34+/CD38− stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin (2012) (58)
Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F. (2008) (58)
Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform (2008) (58)
Basophils are not the key antigen‐presenting cells in allergic patients (2012) (57)
Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. (2014) (57)
Detection of novel leukocyte differentiation antigens on basophils and mast cells by HLDA8 antibodies (2006) (57)
International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. (2019) (57)
Evaluation of the prognostic significance of Eosinophilia and Basophilia in a larger cohort of patients with myelodysplastic syndromes (2010) (57)
Smouldering Mastocytosis: A Novel Subtype of Systemic Mastocytosis with Slow Progression (2002) (57)
Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse (2004) (56)
Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. (2007) (56)
Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. (2001) (56)
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily (2011) (56)
The serum tryptase test: an emerging robust biomarker in clinical hematology (2014) (56)
Ibuprofen inhibits pyrogen-dependent expression of VCAM-1 and ICAM-1 on human endothelial cells. (1996) (55)
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells (2018) (55)
Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches (2019) (55)
Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine (2016) (55)
The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells (2011) (55)
Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. (2011) (55)
Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. (2010) (55)
Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. (2015) (55)
Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications. (2013) (54)
Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. (2017) (54)
Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and CD117/c-kit. (1995) (54)
The surface membrane antigen phenotype of human blood basophils (1994) (54)
Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis (2003) (54)
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. (2018) (54)
Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy (2014) (53)
Developmental, Malignancy-Related, and Cross-Species Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression (2011) (53)
Assays for measuring in vitro basophil activation induced by recombinant allergens. (2004) (52)
Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. (2006) (52)
Low blood counts: immune mediated, idiopathic, or myelodysplasia. (2012) (52)
On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts (2004) (52)
Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia (2016) (52)
MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis (2019) (51)
Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation (2008) (51)
Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice (2016) (51)
Novel targeted therapies for eosinophil-associated diseases and allergy. (2015) (51)
New Aspects in Thrombotic Research: Complement Induced Switch in Mast Cells from a Profibrinolytic to a Prothrombotic Phenotype (2003) (51)
Mast cell-derived proteases control allergic inflammation through cleavage of IgE. (2008) (51)
STAT5BN642H is a driver mutation for T cell neoplasia (2017) (51)
Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. (2000) (51)
Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. (2015) (50)
Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells (2015) (50)
A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone. (1996) (50)
Detection of differentiation‐ and activation‐linked cell surface antigens on cultured mast cell progenitors (2005) (50)
Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. (2002) (50)
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. (2017) (50)
Characterization of Wild-Type Recombinant Bet v 1a as a Candidate Vaccine against Birch Pollen Allergy (2005) (49)
Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation (2005) (49)
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis—Masters of Survival and Clonality? (2016) (49)
High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V (2010) (49)
Expression, epitope analysis, and functional role of the LFA-2 antigen detectable on neoplastic mast cells. (2001) (49)
The IgE-reactive autoantigen Hom s 2 induces damage of respiratory epithelial cells and keratinocytes via induction of IFN-gamma. (2008) (49)
The myeloma stem cell concept, revisited: from phenomenology to operational terms (2016) (48)
Monosomal karyotype in MDS: explaining the poor prognosis? (2013) (48)
DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia (2014) (48)
Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS) (2010) (48)
Type beta transforming growth factors promote interleukin-3 (IL-3)-dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils. (1992) (48)
CD203c is Overexpressed on Neoplastic Mast Cells in Systemic Mastocytosis and is Upregulated upon IgE Receptor Cross-Linking (2008) (48)
Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML (2015) (48)
Inhibition of stem cell factor dependent formation of human mast cells by interleukin-3 and interleukin-4. (1994) (48)
Midostaurin: a magic bullet that blocks mast cell expansion and activation (2017) (47)
Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis (2008) (47)
Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome (2000) (47)
Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. (2007) (47)
Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2 (2007) (47)
Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells. (1991) (47)
Molecular Characterization of Polygalacturonases as Grass Pollen-Specific Marker Allergens: Expulsion from Pollen via Submicronic Respirable Particles1 (2004) (47)
Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. (1996) (46)
Nilotinib Exerts Direct Pro-Atherogenic and Anti-Angiogenic Effects On Vascular Endothelial Cells: A Potential Explanation For Drug-Induced Vasculopathy In CML (2013) (46)
Characterization of Folded Recombinant Der p 5, a Potential Diagnostic Marker Allergen for House Dust Mite Allergy (2008) (46)
123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. (1996) (46)
Leukemic challenge unmasks a requirement for PI3Kdelta in NK cell-mediated tumor surveillance. (2008) (46)
Cytokines involved in growth and differentiation of human basophils and mast cells (1995) (45)
Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML (2019) (45)
In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. (2010) (45)
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study (2010) (45)
Interleukin-3 Promotes the Expression of E-NPP3/CD203C on Human Blood Basophils in Healthy Subjects and in Patients with Birch Pollen Allergy (2007) (45)
Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: A diagnostic challenge (2010) (45)
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category (2006) (44)
Familial hypertryptasemia with associated mast cell activation syndrome. (2014) (44)
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities (2011) (44)
Expression of homing receptors and related molecules on human mast cells and basophils: a comparative analysis using multi-color flow cytometry and toluidine blue/immunofluorescence staining techniques. (1999) (44)
Clinical and Laboratory Parameters of Mast Cell Activation as Basis for the Formulation of Diagnostic Criteria (2011) (44)
Amplification of the AML1(CBFA2) gene on ring chromosomes in a patient with acute myeloid leukemia and a constitutional ring chromosome 21. (2001) (43)
Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. (2015) (43)
Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. (2008) (43)
Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. (2002) (43)
Morphologic and Immunophenotypic Properties of Neoplastic Cells in a Case of Mast Cell Sarcoma (2003) (43)
MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity (2018) (43)
What Have Mast Cells To Do with Edema Formation, the Consecutive Repair and Fibrinolysis? (1997) (43)
Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells. (2007) (43)
Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth (2016) (43)
In Human Macrophages the Complement Component C5a Induces the Expression of Oncostatin M via AP-1 Activation (2008) (43)
Diagnostic evaluation and classification of mastocytosis. (2006) (43)
CCI-779 plus Cisplatin Is Highly Effective against Human Melanoma in a SCID Mouse Xenotranplantation Model (2007) (43)
Identification of oncostatin M as a JAK2 V617F‐dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms (2012) (43)
Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. (2001) (42)
Profilin, a Novel Plant Pan-Allergen. (1992) (42)
Induction of IgE antibodies with predefined specificity in rhesus monkeys with recombinant birch pollen allergens, Bet v 1 and Bet v 2. (1996) (42)
IL-3 promotes basophilic differentiation of KU812 cells through high affinity binding sites. (1990) (42)
Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. (2010) (42)
Tryptase a Novel Biochemical Marker of Acute Myeloid Leukemia (2002) (41)
Chronic myelogenous leukemia and myeloproliferative disease. (2004) (41)
Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts (2018) (41)
Overexpression of primary microRNA 221/222 in acute myeloid leukemia (2013) (41)
Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A Review (2010) (41)
Kit ligand/mast cell growth factor-independent differentiation of mast cells in myelodysplasia and chronic myeloid leukemic blast crisis. (1994) (41)
Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V (2013) (41)
Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. (2003) (40)
Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes. (2007) (40)
Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia (2014) (40)
O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies (2017) (40)
A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val. (2001) (40)
Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells (2017) (40)
Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing. (2014) (40)
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in AML and CML. (2020) (39)
Carrier‐bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen‐induced basophil activation in allergic patients (2012) (39)
Diagnosis, progression patterns and prognostication in mastocytosis (2012) (39)
Stem cell factor-induced downregulation of c-kit in human lung mast cells and HMC-1 mast cells. (1996) (39)
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia (2014) (39)
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal (2021) (39)
Induced gene expression of the hypusine-containing protein eukaryotic initiation factor 5A in activated human T lymphocytes. (1994) (39)
Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression. (2012) (39)
Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis (2018) (39)
Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms (2015) (38)
Evaluation of angiogenesis and vascular endothelial growth factor expression in the bone marrow of patients with aplastic anemia. (2006) (38)
IFN-γ–enhanced allergen penetration across respiratory epithelium augments allergic inflammation (2005) (38)
BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils (2017) (38)
Mastocytosis: a disease of the hematopoietic stem cell. (2008) (38)
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. (2006) (37)
Effects of various statins on cytokine‐dependent growth and IgE‐dependent release of histamine in human mast cells (2006) (37)
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS (2020) (37)
Gliotoxin is a potent NOTCH2 transactivation inhibitor and efficiently induces apoptosis in chronic lymphocytic leukaemia (CLL) cells (2013) (37)
Reducing allergenicity by altering allergen fold: a mosaic protein of Phl p 1 for allergy vaccination (2009) (37)
Impact of age and comorbidity in myelodysplastic syndromes. (2008) (37)
Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML (2019) (37)
Mast cell-lineage versus basophil lineage involvement in myeloproliferative and myelodysplastic syndromes: diagnostic role of cell-immunophenotyping. (1996) (37)
Targeting of VEGF‐dependent transendothelial migration of cancer cells by bevacizumab (2010) (37)
Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5. (2014) (37)
H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells. (2010) (37)
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. (2016) (36)
Metal ion-induced toxic histamine release from human basophils and mast cells. (1998) (36)
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA. (2014) (36)
Diagnosis and management of mastocytosis: an emerging challenge in applied hematology. (2015) (36)
Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia. (2005) (36)
Human leukaemic stem cells: a novel target of therapy (2004) (36)
5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. (2012) (36)
Phenotypic and functional characterization of mast cells derived from renal tumor tissues. (1998) (35)
The pan‐Bcl‐2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells (2014) (35)
A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6 (2008) (35)
Interleukin‐13 promoter gene polymorphism ‐1112C/T is associated with the systemic form of mastocytosis (2009) (35)
Frequent occurrence of T cell–mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments (2015) (35)
High Precision Individual Tree Diameter and Perimeter Estimation from Close-Range Photogrammetry (2018) (35)
Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches (2007) (35)
An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL) (2006) (35)
The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells. (2012) (34)
Altered IgE epitope presentation: A model for hypoallergenic activity revealed for Bet v 1 trimer. (2011) (34)
Characterization of recombinant cat albumin (2003) (34)
A randomized, open‐label, phase I/II trial to investigate the maximum tolerated dose of the Polo‐like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia (2013) (34)
Cerivastatin and atorvastatin inhibit IL‐3‐dependent differentiation and IgE‐mediated histamine release in human basophils and downmodulate expression of the basophil‐activation antigen CD203c/E‐NPP3 (2003) (34)
Bone Marrow Microvessel Density and it's Prognostic Significance in AML (2004) (33)
Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. (2007) (33)
Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis. (2011) (33)
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy (2007) (33)
A case of smouldering mastocytosis with peripheral blood eosinophilia and lymphadenopathy. (2002) (33)
The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers (2006) (33)
Small-molecule inhibition of BRD 4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia ( AML ) (2013) (33)
Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction (2014) (33)
Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease. (2004) (33)
The immunoglobulin-like modules Cε3 and α2 are the minimal units necessary for human IgE-FcεRI interaction (1999) (33)
Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific Immunotherapy (1999) (33)
High level expression of birch pollen profilin (Bet v 2) in Escherichia coli: purification and characterization of the recombinant allergen. (1995) (33)
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders (2021) (32)
The chemokine interleukin‐8 and the surface activation protein CD69 are markers for Bcr–Abl activity in chronic myeloid leukemia (2008) (32)
Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination. (2011) (32)
European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives (2012) (32)
Activation of Human Mast Cells through Stem Cell Factor Receptor (KIT) Is Associated with Expression of bcl-2 (2002) (32)
Disruption of Allergenic Activity of the Major Grass Pollen Allergen Phl p 2 by Reassembly as a Mosaic Protein1 (2008) (32)
Twins with different personalities: STAT5B—but not STAT5A—has a key role in BCR/ABL-induced leukemia (2019) (32)
Interleukin-4 counteracts pyrogen-induced downregulation of thrombomodulin in cultured human vascular endothelial cells (1991) (32)
A case of bone marrow mastocytosis associated with multiple myeloma (1998) (32)
Characterization of human prostate mast cells and their increase in periprostatic vein thrombosis. (2001) (32)
Characterization of IgE–Reactive Autoantigens in Atopic Dermatitis 1. Subcellular Distribution and Tissue–Specific Expression (1999) (32)
Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. (2007) (32)
Genetic Engineering of the Major Timothy Grass Pollen Allergen, Phl p 6, to Reduce Allergenic Activity and Preserve Immunogenicity1 (2007) (31)
Gain of structure and IgE epitopes by eukaryotic expression of the major Timothy grass pollen allergen, Phl p 1 (2004) (31)
Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems (2001) (31)
Proposed diagnostic criteria and classification of basophilic leukemias and related disorders (2017) (31)
Thrombin Augments Vascular Cell-dependent Migration of Human Mast Cells: Role of MGF (1997) (31)
Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects (2016) (31)
Effects of the CD33-targeted drug gemtuzumab ozogamicin (Mylotarg) on growth and mediator secretion in human mast cells and blood basophils. (2007) (31)
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia (2017) (31)
Mast cell differentiation antigens: expression in normal and malignant cells and use for diagnostic purposes (1995) (30)
Differential expression of cell surface integrins on human mast cells and human basophils (1992) (30)
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine (2020) (30)
The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. (2019) (30)
Neoplastic stem cells: current concepts and clinical perspectives. (2010) (30)
The Immunoglobulin E–Allergen Interaction: A Target for Therapy of Type IAllergic Diseases (1998) (30)
CDK6 is an essential direct target of NUP98-fusion proteins in acute myeloid leukemia. (2020) (29)
Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. (2019) (29)
RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis (2021) (29)
Allergen cleavage by effector cell‐derived proteases regulates allergic inflammation (2006) (29)
ICON: Eosinophil Disorders (2012) (29)
Immunophenotypic and functional characterization of human tonsillar mast cells (1997) (29)
Urticaria pigmentosa and mastocytosis: The role of immunophenotyping in diagnosis and determining response to treatment (2006) (29)
A Hypoallergenic Vaccine Obtained by Tail-to-Head Restructuring of Timothy Grass Pollen Profilin, Phl p 12, for the Treatment of Cross-Sensitization to Profilin1 (2007) (29)
Expression of angiogenic factors in chronic myeloid leukaemia: role of the bcr/abl oncogene, biochemical mechanisms, and potential clinical implications (2004) (29)
Risk factors and management of severe life‐threatening anaphylaxis in patients with clonal mast cell disorders (2014) (28)
Successful treatment with arsenic trioxide of a patient with ATRA-resistant relapse of acute promyelocytic leukemia (1999) (28)
Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis. (2018) (28)
“Occult” mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis (2006) (28)
Targeting of mTOR is associated with decreased growth and decreased VEGF expression in acute myeloid leukaemia cells (2009) (28)
NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells (2010) (28)
Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM). (2013) (28)
Hyperfibrinolysis in a case of myelodysplastic syndrome with leukemic spread of mast cells (1999) (28)
Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis. (2002) (28)
Molecular, Structural and Immunological Characterization of Der p 18, a Chitinase-Like House Dust Mite Allergen (2016) (28)
Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. (2014) (28)
Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7 (2006) (28)
Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. (2011) (27)
Quantification of human diamine oxidase. (2017) (27)
Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes (2009) (27)
Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML (2014) (27)
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia (2019) (27)
CD52 is a molecular target in advanced systemic mastocytosis (2014) (27)
Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT. (2006) (27)
Tumor necrosis factor alpha and interleukin-1 beta mRNA expression in HMC-1 cells: differential regulation of gene product expression by recombinant interleukin-4. (1993) (27)
Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia (2015) (27)
Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification (2020) (27)
The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis (2018) (27)
Role of interleukins in the regulation of basophil development and secretion (2010) (27)
BRD4: A BET(ter) target for the treatment of AML? (2014) (27)
CD33 as a target of therapy in acute myeloid leukemia: current status and future perspectives (2005) (27)
Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial (2014) (27)
Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study (2003) (27)
Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin E1, I2, and a D2 receptor. (1992) (26)
Phenotyping and Target Expression Profiling of CD34+/CD38− and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia (2018) (26)
A molecular model of type I allergy: identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcepsilonRI interaction and reacts with receptor-bound IgE. (2001) (26)
Aleukemic Mast Cell Leukemia with Abnormal Immunophenotype and C-kit Mutation D816V (2004) (26)
Expression of cell surface antigens on mast cells: mast cell phenotyping. (2006) (26)
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study. (2021) (26)
Bone Marrow Mastocytosis Associated with IgM Kappa Plasma Cell Myeloma (2004) (26)
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM) (2021) (26)
The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. (2014) (26)
A high‐affinity monoclonal anti‐IgE antibody for depletion of IgE and IgE‐bearing cells (2008) (26)
The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. (2006) (25)
Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers. (1997) (25)
Massive release of the histamine‐degrading enzyme diamine oxidase during severe anaphylaxis in mastocytosis patients (2019) (25)
High-level expression in Escherichia coli and purification of recombinant plant profilins: comparison of IgE-binding capacity and allergenic activity. (1996) (25)
Proteome analysis identifies L1CAM/CD171 and DPP4/CD26 as novel markers of human skin mast cells (2017) (25)
Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998. (1999) (25)
A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens (2019) (25)
Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications. (2017) (25)
Multidisciplinary Management of Mastocytosis: Nordic Expert Group Consensus. (2016) (25)
Chronic myeloid leukemia: Pathophysiology, diagnostic parameters, and current treatment concepts (2003) (25)
In vitro and in vivo studies of three radiolabelled somatostatin analogues:123I-Octreotide (OCT),123I-Tyr-3-OCT and111In-TIRA-d-Phe-1-OCT (1996) (25)
Mast cells are augmented in deep vein thrombosis and express a profibrinolytic phenotype. (1999) (24)
Mast cell activation syndrome: Importance of consensus criteria and call for research. (2018) (24)
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. (2017) (24)
IgA cross‐reactivity between a nuclear autoantigen and wheat proteins suggests molecular mimicry as a possible pathomechanism in celiac disease (2001) (24)
In vivo effects of imatinib mesylate on human haematopoietic progenitor cells (2006) (24)
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. (2020) (24)
Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma (2016) (24)
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. (2016) (24)
Targeting the JAK2-STAT5 pathway in CML. (2014) (24)
Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors (2016) (24)
A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia (2004) (23)
The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils (2012) (23)
The underestimated role of basophils in Ph+ chronic myeloid leukaemia (2018) (23)
Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens (2003) (23)
KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial (2012) (23)
Thinning trainer based on forest-growth model, virtual reality and computer-aided virtual environment (2018) (23)
Estimating the effectiveness of crop management on reducing flood risk and sediment transport on hilly agricultural land – A Myjava case study, Slovakia (2019) (23)
CDK6 coordinates JAK2 V617F mutant MPN via NF-κB and apoptotic networks. (2019) (23)
Myelodysplastic syndromes, aging, and age: Correlations, common mechanisms, and clinical implications (2007) (23)
Purification, Structural and Immunological Characterization of a Timothy Grass (Phleum pratense) Pollen Allergen, Phl p 4, with Cross-Reactive Potential (2002) (22)
Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy. (2009) (22)
Stem Cell Factor-induced Bone Marrow Mast Cell Hyperplasia Mimicking Systemic Mastocytosis (SM): Histopathologic and Morphologic Evaluation with Special Reference to Recently Established SM-criteria (2002) (22)
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers. (2020) (22)
IgG subclass reactivity to human cardiac myosin in cardiomyopathy patients is indicative of a Th1‐like autoimmune disease (1999) (22)
CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. (2017) (22)
Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia (2008) (22)
Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy (2017) (22)
Inhibition of allergen-induced histamine release from human basophils by cyclosporine A and FK-506. (1997) (22)
Molecular characterization of recombinant T1, a non-allergenic periwinkle (Catharanthus roseus) protein, with sequence similarity to the Bet v 1 plant allergen family. (2003) (22)
Molecular Evolution of Hypoallergenic Hybrid Proteins for Vaccination against Grass Pollen Allergy (2015) (22)
Division of the major birch pollen allergen, Bet v 1, into two non-anaphylactic fragments. (1997) (22)
Dasatinib inhibits the growth and survival of neoplastic human eosinophils (EOL-1) through targeting of FIP1L1-PDGFRalpha. (2008) (22)
Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions (2020) (22)
Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q (2015) (22)
High activation of STAT5A drives peripheral T-cell lymphoma and leukemia (2019) (21)
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis (2017) (21)
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group (2015) (21)
Recombinant Allergens Promote Expression of Aminopeptidase-N (CD13) on Basophils in Allergic Patients (2008) (21)
Hypofibrinogenemia in non-M3 acute myeloid leukemia. Incidence, clinical and laboratory characteristics and prognosis (1998) (21)
Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. (1998) (21)
Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021 (2021) (21)
Differential response of human basophils and mast cells to recombinant chemokines (1995) (21)
Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry (2019) (21)
Evaluation of Mast Cell Activation Syndromes: Impact of Pathology and Immunohistology (2012) (20)
IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases (2002) (20)
Immunophenotypic characterization of human basophils and mast cells. (1995) (20)
Cell Surface Membrane Antigen Phenotype of Human Gastrointestinal Mast Cells (2005) (20)
Human basophils express interleukin-4 receptors (1990) (20)
Clustering of comorbidities is related to age and sex and impacts clinical outcome in myelodysplastic syndromes. (2014) (20)
BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib (2018) (20)
Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal☆ (2017) (20)
Gliotoxin Targets Nuclear NOTCH2 in Human Solid Tumor Derived Cell Lines In Vitro and Inhibits Melanoma Growth in Xenograft Mouse Model (2017) (20)
Utilization of Historical Maps in the Land Use Change Impact Studies: A Case Study from Myjava River Basin (2016) (20)
IFN-gamma-enhanced allergen penetration across respiratory epithelium augments allergic inflammation. (2005) (20)
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study (2017) (20)
Prominin-1 (CD133, AC133) and dipeptidyl-peptidase IV (CD26) are indicators of infinitive growth in colon cancer cells. (2015) (20)
Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience. (2011) (20)
NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation (2012) (19)
Mesenchymal stem cells in patients with chronic myelogenous leukaemia or bi-phenotypic Ph+ acute leukaemia are not related to the leukaemic clone. (2007) (19)
Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. (2012) (19)
Recombinant human interleukin 3 induces proliferation of inflammatory cells and keratinocytes in vivo. (1991) (19)
Autocrine fibroblast growth factor 18 signaling mediates Wnt‐dependent stimulation of CD44‐positive human colorectal adenoma cells (2015) (19)
Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML. (2009) (19)
The impact of molecular targets in cancer drug development: major hurdles and future strategies (2013) (19)
Human blood basophils synthesize interleukin-2 binding sites. (1990) (19)
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). (2010) (19)
Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia (2014) (19)
The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma (2018) (19)
Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells (2018) (19)
Mast cells, thrombosis, and fibrinolysis: the emerging concept. (2002) (19)
CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex (2019) (19)
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. (2014) (18)
Monoclonal B‐cell lymphocytosis (MBL) with normal lymphocyte counts is associated with decreased numbers of normal circulating B‐cell subsets (2012) (18)
Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells (2017) (18)
Impact of centralized evaluation of bone marrow histology in systemic mastocytosis (2016) (18)
Does cord blood contain enough progenitor cells for transplantation? (1994) (18)
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536 (2011) (18)
TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes (2019) (18)
Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis. (2008) (18)
CD 33 as a target of therapy in acute myeloid leukemia: current status and future perspectives. (2005) (18)
Estimation of the impact of climate change-induced extreme precipitation events on floods (2015) (18)
High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. (2005) (17)
Recognition Sites for Microbes and Components of the Immune System on Human Mast Cells: Relationship to CD Antigens and Implications for Host Defense (2007) (17)
The protein tyrosine kinase Tec regulates mast cell function (2009) (17)
Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis. (2006) (17)
Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. (2021) (17)
Importance of adequate diagnostic work-up for correct diagnosis of advanced systemic mastocytosis. (2020) (17)
Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry (2008) (17)
Myelomastocytic leukemia: histopathological features, diagnostic criteria and differential diagnosis (2014) (17)
The European Competence Network on Mastocytosis (2004) (17)
Effects of dental amalgam and heavy metal cations on cytokine production by peripheral blood mononuclear cells in vitro. (1998) (17)
Myelodysplastic Syndromes/Neoplasms: Morphological and Immunohistochemical Features and Standard Evaluation (2011) (17)
KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis (2019) (17)
Cold antibody autoimmune hemolytic anemia and lymphoproliferative disorders: a retrospective study of 20 patients including clinical, hematological, and molecular findings (2014) (17)
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study. (2021) (17)
Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation. (2009) (16)
The value of ASCAT soil moisture and MODIS snow cover data for calibrating a conceptual hydrologic model (2020) (16)
Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor? (2010) (16)
FIP1L1/PDGFRA is a molecular marker of chronic eosinophilic leukaemia but not for systemic mastocytosis (2007) (16)
Mixed‐lineage eosinophil/basophil crisis in MDS: a rare form of progression (2008) (16)
Trimolecular Complex Formation of IgE, FcεRI, and a Recombinant Nonanaphylactic Single-Chain Antibody Fragment with High Affinity for IgE 1 (2009) (16)
Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis (2020) (16)
Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia (1998) (16)
Cytogenetic Risk Features in MDS-Update and Present State. (2009) (16)
Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML. (2014) (16)
Proposed score for survival of patients with myelodysplastic syndromes (2013) (16)
Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation (2016) (16)
Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse (2005) (16)
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. (2021) (16)
Induction of Apoptosis in the Human Mast Cell Leukemia Cell Line HMC-1 by Various Antineoplastic Drugs (2003) (16)
Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib. (2005) (16)
Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis. (1998) (16)
Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis (2013) (16)
Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens (2007) (16)
Phorbol ester 12-O-tetradecanoylphorbol-13-acetate down-regulates expression of the c-kit proto-oncogene product. (1993) (15)
Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit) (2018) (15)
A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL (2013) (15)
Lenalidomide therapy in systemic mastocytosis. (2009) (15)
Correlation of Cytogenetic Findings with Morphology, Clinical Course and Prognosis in 2124 Patients with MDS. (2005) (15)
Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. (2020) (15)
Expression of fibrinolytic antigens in redistributed cardiac mast cells in auricular thrombosis. (1997) (15)
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. (2018) (15)
Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas (2017) (15)
Low erythropoietin production as non-oncogenic co-factor contributing to disease-manifestation in low-risk MDS: a hypothesis supported by unique case reports. (2008) (15)
KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). (2010) (14)
Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer. (2021) (14)
Preclinical human models and emerging therapeutics for advanced systemic mastocytosis (2018) (14)
Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study (2017) (14)
E- and P-Selectins Are Essential for Repopulation of Chronic Myelogenous and Chronic Eosinophilic Leukemias in a Scid Mouse Xenograft Model (2013) (14)
CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. (2018) (14)
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis (2021) (14)
Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms (2018) (14)
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) (2019) (14)
Comparative analysis of IL6 and IL6 receptor gene polymorphisms in mastocytosis (2013) (14)
Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: a multicenter retrospective study. (2013) (14)
Chemotherapy in canine acute megakaryoblastic leukemia: a case report and review of the literature. (2009) (14)
Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis (2019) (14)
FDG positron emission tomography in patients with systemic mastocytosis. (2002) (14)
Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia (2019) (14)
Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. (2005) (14)
Effects of interferon-α2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis (2000) (14)
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis (2021) (14)
Controversies and open questions in the definitions and classification of the hypereosinophilic syndromes and eosinophilic leukemias. (2012) (14)
Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia. (2018) (14)
Eosinophil, basophil, and mast cell infiltrates in the bone marrow: crossing the boundaries of diagnosis (2011) (13)
Amplification of ribosomal RNA genes in acute myeloid leukemia (2001) (13)
Bone marrow mastocytosis associated with an undifferentiated extramedullary tumor of hemopoietic origin. (1997) (13)
Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches (2011) (13)
FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H☆ (2013) (13)
Functional characterization, localization, and inhibitor sensitivity of the TPR‐FGFR1 fusion in 8p11 myeloproliferative syndrome (2016) (13)
Splenic Mastocytosis: Report of Two Cases and Detection of the Transforming Somatic C-KIT Mutation D816V (2004) (13)
Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis (2021) (13)
The European Competence Network on Mastocytosis (ECNM). (2004) (13)
Autoantibody Reactivity in a Case of Schnitzler’s Syndrome: Evidence for a Th1-Like Response and Detection of IgG2 Anti-FcεRIα Antibodies (2000) (13)
Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes (2001) (13)
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). (2021) (13)
Epitope specificity determines cross‐protection of a SIT‐induced IgG4 antibody (2015) (12)
Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial (2013) (12)
Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q). (2009) (12)
Immunophenotypic characterization of human bone marrow endosteal cells. (1999) (12)
[Aleukemic mast cell leukemia (formerly: "malignant mastocytosis"): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis]. (2002) (12)
Phenotyping of Human Melanoma Cells Reveals a Unique Composition of Receptor Targets and a Subpopulation Co-Expressing ErbB4, EPO-R and NGF-R (2014) (12)
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2020) (12)
Evolution of Urticaria Pigmentosa into Indolent Systemic Mastocytosis: Abnormal Immunophenotype of Mast Cells without Evidence of c-kit Mutation ASP-816-VAL (2003) (12)
Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal (2021) (12)
Nilotinib Exerts Direct Effects on Vascular Endothelial Cells and May Act As a Co-Trigger of Atherosclerosis in Patients with Ph+ CML (2011) (12)
Searching for Pareto Fronts for Forest Stand Wind Stability by Incorporating Timber and Biodiversity Values (2020) (12)
Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage (2015) (12)
Up-regulation of LDL-receptor expression by LDL-immunoapheresis in patients with familial hypercholesterolemia. (1999) (12)
NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors (2015) (12)
Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V+ Advanced Systemic Mastocytosis (2015) (12)
A STAT5B-CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. (2021) (12)
The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and Beyond. (2019) (12)
Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet (2021) (11)
TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML (2017) (11)
Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management. (2020) (11)
Recombinant allergens. Steps on the way to diagnosis and therapy of type I allergy. (1996) (11)
Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells (2019) (11)
Probability of remaining in unsustained complete remission after steroid therapy withdrawal in patients with primary warm-antibody reactive autoimmune hemolytic anemia (2016) (11)
Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform (2008) (11)
Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). (2007) (11)
The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis (2016) (11)
Isolation of a high‐affinity Bet v 1‐specific IgG‐derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments (2018) (11)
New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019 (2019) (11)
COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms (2021) (11)
An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis (2020) (11)
The impact of COVID‐19 on cancer care of outpatients with low socioeconomic status (2022) (11)
Indolent systemic mastocytosis associated with atypical small lymphocytic lymphoma: a rare form of concomitant lymphoproliferative disease. (2008) (11)
TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors (2020) (11)
Update on genetic and molecular markers associated with myelodysplastic syndromes (2009) (11)
Redistribution, Homing and Organ-Invasion of Neoplastic Stem Cells in Myeloid Neoplasms. (2020) (11)
Eosinophils and eosinophil-associated disorders: immunological, clinical, and molecular complexity (2021) (11)
Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRPα), CD47, and SHP‐1 (2005) (11)
Transposon-mediated generation of BCR-ABL1-expressing transgenic cell lines for unbiased sensitivity testing of tyrosine kinase inhibitors (2016) (11)
Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post‐induction consolidation therapy (2016) (11)
Characterization of LDL and VLDL binding sites on human basophils and mast cells. (1995) (11)
Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophils (2013) (11)
Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes (2003) (11)
Prognosis of patients with a second relapse of acute myeloid leukemia (2000) (11)
Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia—A Retrospective Analysis in 337 Patients (2020) (10)
Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond (2021) (10)
Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis (2021) (10)
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS‐Flow Cytometry Working Group (2021) (10)
Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia (2018) (10)
Analysis of Nitrate Concentrations Using Nonlinear Time Series Models (2011) (10)
STAT5 is Expressed in CD34+/CD38− Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms (2020) (10)
Meeting report: Vienna 2008 Workshop of the German–Austrian Working Group for Studying Prognostic Factors in Myelodysplastic Syndromes (2009) (10)
Global Classification of Mast Cell Activation Disorders An ICD-10-CM-Adjusted Proposal of the ECNM-AIM Consortium. (2022) (10)
Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib (2018) (10)
New and Comprehensive Cytogenetic Prognostication and Categorization in MDS. (2006) (9)
Oncostatin M is a FIP1L1/PDGFRA‐dependent mediator of cytokine production in chronic eosinophilic leukemia (2013) (9)
Standards and standardization in mastocytosis (2007) (9)
JAK‐STAT core cancer pathway: An integrative cancer interactome analysis (2022) (9)
Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia (2006) (9)
Human basophils express interleukin-4 receptors. (1990) (9)
In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia (2016) (9)
Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. (2011) (9)
Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT. (2014) (9)
An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) (2015) (9)
Improvement of cardiac function, mitral regurgitation and pulmonary hypertension in a patient with chronic eosinophilic leukemia (CEL) after low dose imatinib therapy. (2008) (9)
Effect of statins on lipoprotein receptor expression in cell lines from human mast cells and basophils (2003) (9)
The Transcription Factor MAZR Preferentially Acts as a Transcriptional Repressor in Mast Cells and Plays a Minor Role in the Regulation of Effector Functions in Response to FcεRI Stimulation (2013) (9)
Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes (2022) (9)
Ponatinib Exerts Multiple Effects on Vascular Endothelial Cells: Possible Mechanisms and Explanations for the Adverse Vascular Events Seen in CML Patients Treated with Ponatinib (2016) (9)
Clonal Hematopoiesis of Indeterminate Potential: A Multidisciplinary Challenge in Personalized Hematology (2020) (9)
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions. (2012) (9)
Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib (2007) (9)
A patient with de novo AML M1 and t(16;21) with karyotype evolution. (2007) (8)
Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia (2021) (8)
Type beta transforming growth factors promote interleukin-3 (IL-3)- dependent differentiation of human basophils but inhibit IL-3-dependent differentiation of human eosinophils (1992) (8)
Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates with reduced allergenic activity (2019) (8)
STAT 5 B N 642 H is a driver mutation for T cell neoplasia (2018) (8)
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML (2019) (8)
Evaluation of neoplastic human mast cells by tryptase‐immunoelectron microscopy (2006) (8)
Stable non-transforming minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia after autologous transplantation: origin from neoplastic yet ‘pre-leukemic’ stem cells? (2011) (8)
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms (2019) (8)
Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022 (2022) (8)
The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. (2018) (8)
Interleukin-33: a regulator of basophils. (2009) (8)
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. (2022) (8)
Results from a Genome-Wide Association Study (GWAS) in Mastocytosis Reveal New Gene Polymorphisms Associated with WHO Subgroups (2020) (8)
Drug-Induced Mast Cell Eradication: A Novel Approach to Treat Mast Cell Activation Disorders? (2022) (8)
KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6 (2020) (8)
Numbers of colony‐forming progenitors in patients with systemic mastocytosis: potential diagnostic implications and comparison with myeloproliferative disorders (2003) (8)
The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells (2017) (8)
Assessment of The Uncertainties of a Conceptual Hydrologic Model By Using Artificially Generated Flows (2012) (8)
Dasatinib inhibits progenitor cell proliferation from polycythaemia vera (2008) (8)
miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool (2021) (7)
Expression of a Major Plant Allergen as Membrane-Anchored and Secreted Protein in Human Cells with Preserved T Cell and B Cell Epitopes (2011) (7)
Normal bone marrow function over 6 years in a patient with dysplastic hematopoiesis and a complex karyotype. (2004) (7)
Growing evidence for an underestimation of poor-risk cytogenetics in the international prognostic scoring system in myelodysplastic syndromes (2007) (7)
Characteristics and process controls of statistical flood moments in Europe – a data-based analysis (2021) (7)
cFinder: definition and quantification of multiple haplotypes in a mixed sample (2015) (7)
Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno‐occlusive disease? (2016) (7)
Cytokinetic Resistance in Acute Leukemia: Recombinant Human Granulocyte Colony-Stimulating Factor, Granulocyte Macrophage Colony-Stimulating Factor, Interleukin-3 and Stem Cell Factor Effects In Vitro and Clinical Trials with Granulocyte Macrophage Colony-Stimulating Factor (1992) (7)
Pooled Survival Analysis Of Midostaurin Clinical Study Data (D2201+A2213) In Patients With Advanced Systemic Mastocytosis Compared With Historical Controls (2017) (7)
Basophil Activation Antigens: Molecular Mechanisms and Clinical Implications (2010) (7)
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group (2015) (7)
Further Evaluation of Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib in Mice and in Patients with Ph-Chromosome plus CML (2014) (7)
Identification of a Neoplastic Stem Cell in Human Mast Cell Leukemia (2014) (7)
Cell‐based and antibody‐mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues (2020) (7)
Dasatinib-induced immunosuppression and recurrent respiratory tract infections (2015) (7)
Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis (2022) (7)
Clinical Impact and Proposed Application of Molecular Markers, Genetic Variants and Cytogenetic Analysis in Mast Cell Neoplasms: Status 2022. (2022) (7)
Detection of Trisomy 8 in Donor-Derived Ph− Cells in a Patient with Ph+ Chronic Myeloid Leukemia Successfully Treated with Imatinib (STI571) in Relapse after Allogeneic Transplantation (2004) (7)
TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment. (2020) (7)
Antibody conjugates bispecific for intercellular adhesion molecule 1 and allergen prevent migration of allergens through respiratory epithelial cell layers (2015) (7)
Systemic mastocytosis. (2008) (7)
Systemic Mastocytosis Associated with Chronic Idiopathic Myelofibrosis A Distinct Subtype of Systemic Mastocytosis-Associated Clonal Hematological Nonmast Cell Lineage Disorder Carrying the Activating Point Mutations KIT D816V and JAK2 V617F (2010) (7)
Evaluation of treatment responses and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic stem cell transplantation: a single-center experience (2014) (7)
Microarray-based Detection of Allergen-Reactive IgE in Patients with Mastocytosis. (2020) (6)
Forest modelling and visualisation – state of the art and perspectives (2019) (6)
Detection of circulating endogenous interleukin-3 in extensive chronic graft-versus-host disease. (1992) (6)
Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry (2014) (6)
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto‐oncogene, receptor tyrosine kinase (KIT) D816V mutations (2021) (6)
Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single ‘hit’ and cooperate in producing a mastocytosis-like disease in mice (2010) (6)
A Novel Fusion Gene NDEL1-Pdgfrb in a Patient with JMML with a New Variant of TKI-Resistant Mutation in the Kinase Domain of PDGFRβ (2014) (6)
Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma (2016) (6)
IL‐4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells (2017) (6)
Evidence for an Underestimation of the Prognostic Impact of Poor Cytogenetics within the IPSS. (2006) (6)
Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 51 (2006) (6)
Treatment concepts for elderly patients with acute myeloid leukemia (2003) (6)
KIT as a master regulator of the mast cell lineage. (2022) (6)
Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. (1992) (6)
c-kit D816V Provides a Strong Signal for Myelomastocytic Differentiation and Cluster Formation in Murine Ba/F3 Cells. (2004) (6)
Chapter 31 – Role of Mast Cells in Endogenous Fibrinolysis and Related (Patho)physiological Processes (2000) (6)
Intensive consolidation with G‐CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years (2017) (6)
Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia (2008) (6)
[Radioimmunometric determination of histamine in myeloproliferative syndromes]. (1989) (6)
Calculating Areal Ranfall Using A More Efficient Idw Interpolation Algorithm (2015) (6)
Variability of PD-L1 expression in mastocytosis. (2018) (6)
[Individualized management and therapy of myelodysplastic syndromes]. (2008) (6)
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia (2022) (6)
Characterization of mutants of a highly cross-reactive calcium-binding protein from Brassica pollen for allergen-specific immunotherapy. (2013) (6)
Immunophenotypic analysis of HL-60 cells during basophilic differentiation. (1996) (6)
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis (2022) (6)
12 Updated cytogenetic risk features in MDS – present state (2009) (5)
Does high‐dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia? (2013) (5)
Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference. (2021) (5)
Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial (2008) (5)
[Tumor stem cell research - basis and challenge for diagnosis and therapy]. (2010) (5)
Mast cell leukemia--a rare form of myeloid leukemia. (2002) (5)
Anaemia of the elderly (AOE): does it exist and does it matter in clinical practice? (2008) (5)
Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin (2020) (5)
Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients (2008) (5)
The Leukemic Stem Cell (LSC) in Ph+ CML Is a CD34+/CD38−/Lin− Cell That Co-Expresses Dipeptidylpeptidase IV (CD26) and Disrupts LSC-Niche Interactions by Degrading the CXCR4 Ligand SDF-1α (2011) (5)
Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (2021) (5)
Prognostic factors and follow-up parameters in patients with paroxysmal nocturnal hemoglobinuria (PNH): experience of the Austrian PNH network (2020) (5)
Scoring the risk of having systemic mastocytosis in adult patients with mastocytosis in the skin. (2020) (5)
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions (2021) (5)
The In Vivo Effects of IL-3 and GM-CSF in Primates (1990) (5)
Cardiovascular Scoring and Age-Related Mutations Predict the Occurrence of Adverse Vascular Events in CML Patients during Nilotinib Therapy (2017) (5)
Combination treatment of acute myeloblastic leukemia with rhGM-CSF and standard induction chemotherapy. (1993) (5)
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User´s Guide for Daily Clinical Practice. (2022) (5)
Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality? (2010) (5)
BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML (2018) (5)
A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) – AGMT_CMML-1 (2018) (5)
Signal Transduction—Associated and Cell Activation—Linked Antigens Expressed in Human Mast Cells (2002) (5)
IgE Recognition 4: Structural Basis for Calcium-Modulated Calcium-Binding Alder Pollen Allergen, Aln g of a Highly Cross-Reactive Two EF-Hand Molecular and Immunologic Characterization (1998) (5)
Impact of Climate and Geology on Event Runoff Characteristics at the Regional Scale (2020) (5)
PD‐L1 overexpression correlates with JAK2‐V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms (2022) (5)
New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics (2008) (5)
Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter. (2021) (5)
Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF. (2004) (4)
Autoantibody reactivity in a case of Schnitzler's syndrome: evidence for a Th1-like response and detection of IgG2 anti-FcepsilonRIalpha antibodies. (2000) (4)
The cancer survival index—A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies (2022) (4)
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study Group (2019) (4)
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics (2011) (4)
MAST CELLS AND MAST CELL GROWTH FACTOR: POSSIBLE ROLE IN AURICULAR THROMBOSIS (1995) (4)
Mast Cell Leukemia: Clinical and Molecular Features and Survival Outcomes of Patients in the ECNM Registry. (2022) (4)
A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML. (2019) (4)
The immunoglobulin-like modules Cepsilon3 and alpha2 are the minimal units necessary for human IgE-FcepsilonRI interaction. (1999) (4)
Changes in the snow water equivalent in mountainous basins in Slovakia over recent decades (2015) (4)
Possible therapeutic potential of a recombinant group 2 grass pollen allergen‐specific antibody fragment (2014) (4)
Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry (2014) (4)
Proposed ECNM-AIM Response Criteria in Advanced Systemic Mastocytosis. (2022) (4)
Biology and clinical features of myeloid neoplasms with inv(3) (q21q26) or t(3;3) (q21q26) (2007) (4)
GM-CSF in combination with cytotoxic chemotherapy in AML patients. (1990) (4)
Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine (2022) (4)
Complement receptor expression on basophils and mast cells: Evidence for mast cell heterogeneity (1994) (4)
Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter (2020) (4)
Comorbidity as Prognostic Variable in MDS: Comparative Evaluation of the HCT-CI and CCI in a Core Data Set of 582 Patients of the Austrian MDS Platform. (2008) (4)
Azacitidine in Patients with Acute Myeloid Leukemia: Impact of Intermediate-Risk Vs High-Risk Cytogenetics on Patient Outcomes (2014) (4)
Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet? (2022) (4)
Culturing cells with mast cell phenotype and function: Comparison of peripheral blood and bone marrow as a source. (2021) (4)
Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on Mastocytosis (ECNM). (2021) (4)
The somatostatin receptor (SSTR) subtype 3 ACTS as an acceptor of vasocative intestinal peptide (VIP) (1998) (4)
Nilotinib and Imatinib Are Comparably Effective in Reducing Growth of Human Eosinophil Leukemia Cells in a Newly Established Xenograft Model (2012) (4)
Metabolic drug survey highlights cancer cell dependencies and vulnerabilities (2020) (4)
First annual report of the Austrian CML registry (2010) (4)
Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure (2020) (4)
Targeting Nuclear NOTCH2 by Gliotoxin Recovers a Tumor-Suppressor NOTCH3 Activity in CLL (2020) (4)
Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML, (2011) (4)
The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. (2017) (4)
S1611 MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS (2019) (4)
Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group. (2022) (4)
Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience (2014) (4)
P-113 Revised International Prognostic Scoring System (IPSS-R) for primary treated myelodysplastic syndromes (MDS) patients: A report from the IWG-PM (2013) (4)
Forest land tax reductions – an effective payment for forest ecosystem services in Slovakia? (2021) (4)
O-GlcNAcylation of STAT 5 controls tyrosine phosphorylation and oncogenic transcription in STAT 5-dependent malignancies (2017) (4)
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis proposed by the ECNM-AIM Consortium. (2022) (4)
Mobilization of circulating hemopoietic progenitor cells by rhIL‐3 and rhGM‐CSF in primates (1992) (4)
Mast cells, masters, and mastocytosis: Development of research since the times of Paul Ehrlich (2004) (4)
Modelling the Climate Change Impact On Monthly Runoff in Central Slovakia (2016) (3)
CD 25 high T cells with a prolonged survival inhibit development of diabetes (2009) (3)
Mast Cells, Mastocytosis, and Related Disorders. (2015) (3)
Process-based selection of copula types for flood peak-volume relationships in Northwest Austria: a case study (2016) (3)
Why clinicians should be interested in Interleukin-3 (1990) (3)
Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age (2013) (3)
The Heme Oxygenase-1-Targeting Compound PEG-ZnPP Inhibits Growth of Imatinib-Resistant BCR/ABL-Transformed Cells. (2004) (3)
In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML. (2005) (3)
Phenotypic and Functional Characterization of CD34+/CD38-/CD123+ Leukemic Progenitor (Stem) Cells in AML: a Flow Cytometric Approach. (2008) (3)
Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis (2021) (3)
All systems red (2015) (3)
The IPSS-R has prognostic impact in untreated patients with MDS del(5q). (2015) (3)
Fibroblast Colony Stimulating Activity of GM-CSF and IL-3 in Human Bone Marrow Cell Cultures (1990) (3)
Hypoallergenic Forms of the Ryegrass Pollen Allergen Lol p 5 as Candidates for Immunotherapy (2001) (3)
Overexpression of FcεRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom Anaphylaxis (2022) (3)
Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm (2016) (3)
Clofarabine/cyclophosphamide for debulking before stem cell transplantation (2014) (3)
Angiosarcoma of bone marrow with unusual expression of chymase: diagnosis in a trephine biopsy specimen (2007) (3)
Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS) (2016) (3)
Glucocorticosteroids Rescue Basophils from Dasatinib-Augmented Immunoglobulin E-Mediated Histamine Release (2012) (3)
An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase (2005) (3)
Comorbidity, iron overload and HFE variants: a new prognostic complex in MDS? (2009) (3)
Bosutinib Blocks Lyn and Btk Activation and Synergizes with the KIT D816V-Targeting Drug Midostaurin in Inducing Apoptosis in Neoplastic Human Mast Cells. (2009) (3)
Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia. (2010) (3)
Successful allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia during respiratory failure and invasive mechanical ventilation (2011) (3)
Latent structure and measurement invariance of the Hospital Anxiety and Depression Scale in cancer outpatients (2022) (3)
Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS) (2003) (3)
Diagnosis, management and response criteria of iron overload in myelodysplastic syndromes (MDS): updated recommendations of the Austrian MDS platform (2018) (3)
The epigenetic reader brd4 serves as a novel marker and target in aggressive systemic mastocytosis and mast cell leukemia (2014) (3)
A Joint Sedimentation-Flood Retention Assessment of a Small Water Reservoir in Slovakia: A New Hope for Old Reservoirs? (2019) (3)
Mast cell leukemia: a review (2014) (3)
Effects of vasoactive intestinal peptide (VIP) and somatostatin (SST) on lipoprotein receptor expression by A431 tumor cells. (2001) (3)
Identification of Novel Surface Markers and Targets In Neoplastic Stem Cells In AML and CML: a Flow-Gene-Flow Screen Approach. (2010) (3)
Identification of CAR As a Novel Mediator of Erythroid Differentiation and Migration That Is Specifically Downregulated in Erythropoietic Progenitor Cells in Patients with MDS (2014) (3)
Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype (2020) (3)
Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia (2020) (3)
Prognostic Impact of Additional Chromosomal Aberrations (ACA) to 5q- in Patients with primary Myelodysplastic Syndrome. (2008) (3)
Urticaria and Angioedema: Understanding Complex Pathomechanisms to Facilitate Patient Communication, Disease Management, and Future Treatment. (2023) (2)
Physiology and pathology of eosinophils: Recent developments (2021) (2)
Incidence and Prognostic Impact of Cytogenetics in Combination with Molecular Aberrations in Patients with Systemic Mastocytosis (2016) (2)
Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival (2021) (2)
Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells (2008) (2)
4.P.315 Stimulation of LDL receptor expression by LDL-immuno-apheresis in patients with heterozygous familial hypercholesterolemia (1997) (2)
The Impact of Transfusion-Dependency on the Outcome of Patients with Myelodysplastic Syndromes (MDS) Receiving Allogeneic Peripheral Blood Stem Cell Transplantation after Myeloablative Conditioning. (2007) (2)
Systematic Profiling and Novel Targets of the Bcr-Abl Kinase Inhibitors Imatinib, Nilotinib and Dasatinib. (2007) (2)
Azacitidine in Patients with Acute Myeloid Leukemia: Assessing the Potential Negative Impact of Elevated Baseline White Blood Cell Count on Outcome (2014) (2)
Expression and Regulation of Siglec-6 (CD327) on Human Mast Cells and Basophils. (2022) (2)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (2)
Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia (2014) (2)
Impact of Molecular Markers on Response and Resistance in Midostaurin-Treated Patients with Advanced Systemic Mastocytosis (2016) (2)
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance (2018) (2)
Reciprocal translocation (3;5)(q26;q22) and possible BCHE gene involvement in an unusual myelogenous disorder with both myeloproliferative and dysplastic features. (2000) (2)
Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis (2015) (2)
Oncogene-Induced DNA Repair Defects Promote PARP1-Mediated “Dual Synthetic Lethality” To Eradicate Quiescent and Proliferating Leukemia Stem and Progenitor Cells (2013) (2)
RAS mutations drive proliferative chronic myelomonocytic leukemia via activation of a novel KMT2A-PLK1 axis (2019) (2)
Evaluation of Cell Surface Markers and Targets in Leukemic Stem Cells (LSC) Reveals Distinct Expression Profiles, Unique Drug Effects, and Specific Checkpoint Regulation in AML LSC and CML LSC (2016) (2)
Incidence of Intensive Care Unit Admission, Outcome, and Post Intensive Care Survival in Patients with Acute Lymphocytic Leukemia or Burkitt Lymphoma (2014) (2)
Selection and Efficacy of Cytoreductive Agents in Patients with Mastocytosis Included in the Registry of the European Competence Network on Mastocytosis (ECNM) (2017) (2)
Revealing Six Phases of CML Stem Cell Development to Explain Clinical Phenomena Seen in TKI-Treated Patients. (2009) (2)
Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study (2022) (2)
The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest (2018) (2)
Evaluation of Surface Runoff Generation Processes Using a Rainfall Simulator: A Small Scale Laboratory Experiment (2017) (2)
Clinical, Hematological, and Biologic Characteristics in Chronic Myelomonocytic Leukemia Patients with a JAK2 V617F Mutation (2016) (2)
In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells (2020) (2)
A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders (2021) (2)
BCR/ABL Induces Expression of Vascular Endothelial Growth Factor and its Transcriptional Activator, Hypoxia Inducible Factor-1α, through a Pathway Involving PI3-Kinase and the Mammalian Target of Rapamycin (mTOR) (2002) (2)
Optimizing Use of Water Management Systems during Changes of Hydrological Conditions (2017) (2)
Fetuin in Human Bone Marrow: Detection in Foetal Tissue and Patients with Mastocytosis (2001) (2)
The Hsp32/HO-1-targeted drug SMA-ZnPP counteracts the proliferation and viability of neoplastic cells in solid tumors and hematologic neoplasms (2007) (2)
Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation? (2016) (2)
miRNome profiling of clonal stem cells in Ph+ CML (2020) (2)
Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression on Human Cell Lines and Hematologic Malignancies (2012) (2)
Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives (2018) (2)
Identification of PDGFR blockade as a rational and highly effective therapy for NPM-ALK driven lymphomas (2)
Overexpression of PD-L1 Correlates with JAK2-V617F Mutational Burden and Is Associated with Chromosome 9p Uniparental Disomy in MPN (2020) (2)
High Spontaneous In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia is Associated with Mutations in Rasopathy Genes, Myeloproliferation and Inferior Prognosis (2016) (2)
A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD). (2011) (2)
Targeting Rac2 - Mitochondrial Respiratory Chain Complex III Signaling to Prevent Genomic Instability in Leukemia Stem and Progenitor Cells (2011) (2)
Individualizing IPSS Risk Assessment in Myelodysplastic Syndromes, by Additionally Taking into Account Age, Gender and French-American-British (FAB) Classification - A Multicenter Analysis. (2006) (2)
Appendix A CD Molecules (2014) (2)
Mastocytosis, MCAS, and Related Disorders—Diagnosis, Classification, and Therapy (2021) (2)
Mast Cell Diseases in Practice and Research: Issues and Perspectives Raised by Patients and Their Recommendations to the Scientific Community and Beyond. (2022) (2)
An in vitro Model for the Allergen–IgE–FcεRI Interaction (1999) (2)
A series of case studies illustrating the role of flow cytometry in the diagnostic work‐up of myelodysplastic syndromes (2022) (2)
Classification and Response Criteria in Mast Cell Disorders: Time to Revise? (2011) (2)
Systemic Mastocytosis with Associated Acute Myeloid Leukemia (SM-AML): a Poor-Risk Multi-Mutated Disease That Follows a Distinct Diagnostic Algorithm and Requires High-Dose Stem Cell-Targeting Therapy (2017) (2)
Switching From High-Dose Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuria: A Case Report (2020) (2)
5-Azacytidine and Decitabine Induce Demethylation and Re-Expression of FAS (CD95) and Promote Apoptosis in Neoplastic Cells in Acute Myeloid Leukemia (AML), (2011) (2)
Genetic background of mastocytosis, a synopsis of cooperative studies conducted by ECNM (2013) (2)
Diagnosis and Treatment of Anaphylaxis in Patients with Mastocytosis (2014) (2)
Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis. (2005) (2)
Associations of TNF-alpha gene polymorphisms and mastocytosis. A study of the European competence network in mastocytosis (ECNM) (2008) (2)
An Assessment of Changes in Ecological Stability and Landscape Management Practices over the Last Centuries: A Case Study from Vrbovce, Slovakia (2019) (2)
Partial Characterization and In Vitro Expansion of Putative CLL Precursor/Stem Cells Which Are Dependent on Bone Marrow Microenvironment for Survival (2010) (2)
Mast Cell Leukemia: Clinical Heterogeneity, Molecular Aberrations, Treatment Responses, Survival, and Prognostic Factors (2016) (2)
PI3-kinase inhibition as a strategy to suppress the leukemic stem cell niche in Ph+ chronic myeloid leukemia. (2021) (2)
Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes (2015) (1)
Comment on Gallipoli et al , page 1492 Targeting the JAK 2-STAT 5 pathway in CML---------------------------------------------------------------------------------------------------- - (2014) (1)
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis (2016) (1)
Controversies and Open Questions in the Definitions and Classification of the Hypereosinophilic Syndromes and Eosinophilic Leukemias (2013) (1)
Massive release of Th2 cytokines induced a cytokine storm during a severe mast cell activation event in an indolent systemic mastocytosis patient. (2022) (1)
Use of interleukin-11 to stimulate platelet production in myelodysplastic syndromes (2006) (1)
Acute myeloid leukemia KIT D 816 mutated / CBF-negative acute myeloid leukemia : a poor-risk subtype associated with systemic mastocytosis (2019) (1)
Histidine Decarboxylase (HDC) as Novel Marker of Immature Neoplastic Mast Cells in Systemic Mastocytosis. (2004) (1)
Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms (2021) (1)
Increased lipid desaturation and ovarian cancer stem cells (2017) (1)
P020 Refining prognostic systems by comorbidity: are existing scores sufficient for MDS or may specific scores perform better? (2009) (1)
A Phase I Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukaemia (CMML) – AGMT_CMML 1 (2014) (1)
A methodology for continuous a flood frequency analysis with weather generator and rainfall-runoff model (2019) (1)
Profilin represents a novel plant pan-allergen (1993) (1)
ectonucleotide pyrophosphatase/phosphodiesterase 3 The basophil activation marker defined by antibody 97A6 is identical to the (2013) (1)
R-metHuG-CSF Combined with Chemotherapy for Treatment of Adult ALL — Pilot Study (1994) (1)
PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions. (2005) (1)
The Midostaurin (PKC412) Metabolite CGP52421 Shows Little Growth-Inhibitory Activity Against Against Neoplastic Mast Cells but Retains Inhibitory Effects on IgE-Dependent Activation and Histamine Release (2011) (1)
Expression and secretion of VEGF in solid tumor cells is mediated by the mammalian target of rapamycin (mTOR) (2007) (1)
The Oncogenic Transcription Factor STAT5 Triggers Aberrant Expression Of CD25 (IL-2RA) In Neoplastic Stem Cells In Ph+ CML (2013) (1)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (1)
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes (2022) (1)
Systemic Mastocytosis Associated with Lymphoproliferative Disorders (SM-AHNMD) (2012) (1)
MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment (2018) (1)
Treatment of Patients with Aggressive Systemic Mastocytosis, Mast Cell Leukemia and Mast Cell Sarcoma: A Single Center Experience (2018) (1)
P-111 Time changes in predictive power of MDS prognostic scores – Effects on revised scores such as the IPSS-R, impact of age (2013) (1)
Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα. (2007) (1)
Allergen house dust mite (2007) (1)
BCR/ABL+ CML Stem Cells (CD34+/CD38-) Express High Levels of CD33 and Are Responsive to a CD33-Targeting Drug: a New Potential Concept for Eradication of CML Stem Cells. (2010) (1)
Ponatinib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest and Apoptosis, (2011) (1)
Refinements in response criteria in systemic mastocytosis: reply to a proposal (2010) (1)
Effects of Ponatinib and Other Novel TKI On Growth, Survival, and Function of Neoplastic Eosinophils Carrying FIP1L1/Pdgfra (2012) (1)
Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia (2021) (1)
The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia (2018) (1)
Peritrophic Matrix of Mite Fecal Pellets Allergen Associated with the pteronyssinus Dermatophagoides Protein , as a New Major Identification of Der p 23 , a Peritrophin-like Valenta and (2013) (1)
KIT D816V Mutation Burden Predicts Prognosis and Survival In Patients With Mastocytosis and Correlates With The WHO Type Of The Disease (2013) (1)
Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML) (2019) (1)
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q (2021) (1)
Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia. (2012) (1)
Clinical impact of genetic and molecular markers in myelodysplastic syndromes (MDS) (2009) (1)
Phenotyping Of Leukemic Stem Cells In Ph+ ALL and Ph- ALL Reveals Unique Profiles Of Markers and Targets In Distinct Disease Variants (2013) (1)
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine). (1999) (1)
Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils. (2006) (1)
The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition. (2007) (1)
Abnormal Expression Of The Major Coxsackie-Adenovirus Receptor CAR On Immature Dysplastic CD105+ Erythroid Progenitor Cells In Patients With MDS and Related Bone Marrow Neoplasms (2013) (1)
Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population (2022) (1)
Multistep pathogenesis of chronic myelomonocytic leukemia in patients (2022) (1)
Metabolome and lipidome derangements during a severe mast cell activation event in a patient with indolent systemic mastocytosis. (2021) (1)
NT-Probnp As Personalized Medicine Tool and New Biomarker Predicting Response to Chemotherapy and Survival in AML (2021) (1)
Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry) (2016) (1)
Identification Of The Ki-1 Antigen (CD30) As a Novel Marker and Potential Therapeutic Target In Neoplastic Mast Cells In Advanced Systemic Mastocytosis (2013) (1)
In Vivo Synergism of Interleukin-3 and Interleukin-6 on Thrombopoiesis in Primates (1992) (1)
Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells (2014) (1)
Fibrinolysis Plasminogen Activator Expression and The Mast Cell as Site of Tissue-Type (1998) (1)
Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML. (2006) (1)
37 CAR, A NOVEL MEDIATOR OF ERYTHROID DIFFERENTIATION AND MIGRATION, IS SPECIFICALLY DOWNREGULATED IN ERYTHROPOIETIC PROGENITOR CELLS IN MDS (2015) (1)
Characterization of VEGF Receptors expressed on Human Endothelial Cells and Human Tumor cells (1996) (1)
New Insights Into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy. (2022) (1)
114 The dual PI3K/mTOR blocker NVP-BEZ235 sensitizes cancer cells against irreversible ErbB inhibitors (2010) (1)
Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years (2016) (1)
Karyotype Plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML (≥60 Years) Who Benefit From Intensive Post-Induction Consolidation Therapy (2011) (1)
Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph+ Cml (2016) (1)
A New Prognostic Score for Advanced Systemic Mastocytosis Based on Clinical and Genetic Characteristics of 210 Consecutive Patients (2018) (1)
Extensive Pleural and Pericardial Effusion In 4 CML Patients Treated with Dasatinib at 100 Mg or 50 Mg Once Daily. (2010) (1)
Response to the letter of Dr. Karin Hartmann and Dr. Beate M. Henz (2002) (1)
Major response of PNH to an AML chemotherapy protocol (2018) (1)
Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis (2021) (1)
Flood Frequency Analysis Using Continuous Simulation of Catchment Runoff (2015) (1)
Autoantibodies in Atopic Eczema (2006) (1)
Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1). (2005) (1)
The Aurora-Kinase Inhibitor R763/AS703569 Exerts Major Growth-Inhibitory and Apoptosis-Inducing Effects on Neoplastic Mast Cells (2010) (1)
Syndromes Revised International Prognostic Scoring System for Myelodysplastic (2012) (1)
Phenotyping of Disease-Initiating CD34+/CD38─ Stem Cells in BCR-ABL1─ MPN Reveals Expression of Multiple Cytokine Receptors and Resistance-Related Antigens (2020) (1)
The Role of PPM1D Mutations in Lenalidomide Resistance and Progression in Patients with MDS and Deletion of Chromosome 5q (2018) (1)
206 Downstream signaling pathways determine resistance of cancer cells against novel irreversible ErbB-targeting drugs (2010) (1)
mutated / CBF-negative acute myeloid leukemia (2019) (1)
Detection of Activated STAT5 in Neoplastic Mast Cells in Patients with Systemic Mastocytosis: Role of c-kit D816V. (2005) (1)
Identification of Mcl-1 as a Novel Target in Neoplastic Mast Cells and Demonstration of Cooperative Growth-Inhibitory Effects of mcl-1 Antisense Oligonucleotides, PKC412, and AMN107. (2005) (1)
Novel Developments in AML – ASH 2010 (2011) (1)
Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms (2013) (1)
Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib. (2013) (1)
Deletion of sequences telomeric of the EVI1 gene in 3q26 associated with a novel pericentric inv(3)(p25q26) in a patient with acute myelogenous leukemia. (2003) (1)
Monitoring Changes in the Morphology and Storage of a Small Water Reservoir: A Case Study from Vrbovce, Slovakia (2020) (1)
Red blood cell transfusion-dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndromes (MDS) (2009) (1)
Is there something wrong in paradise? Christian beliefs and the safety of novel BCR/ABL1 inhibitors (2011) (1)
Epitope speciﬁcity determines cross-protection of a SIT-induced IgG 4 antibody (2015) (1)
10th anniversary of the Austrian MDS Platform: aims and ongoing projects (2014) (1)
[Mastocytosis and eosinophilic leukemia: diagnostics and classification]. (2012) (1)
Mastocytosis – A Disease of the Hematopoietic Stem Cell: In reply (2009) (1)
An Application of a Stochastic Semi-Continuous Simulation Method for Flood Frequency Analysis: A Case Study in Slovakia (2017) (1)
Hematopoietic Stem-Cell Transplantation for Advanced SystemicMastocytosis (2014) (1)
Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells (2015) (1)
Review Article Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology (2013) (1)
CALIBRATION OF A LOW-COST 3D PRINTED RAIN GAUGE UTILIZING AN OPEN-SOURCE ARDUINO PLATFORM (2017) (1)
[Effector cells in allergy: biological principles and new pharmacologic concepts]. (1993) (1)
Chapter 72 – Mast Cells and Mastocytosis (2018) (1)
Recent Developments in the Field of Mast Cell Disorders: Classification, Prognostication, and Management. (2022) (1)
Case report of a clinically indolent but morphologically high‐grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma? (2021) (1)
Effects of dental amalgam and its components of histamine release from human basophils and tissue mast cells. (1998) (1)
Vascular Endothelial Growth Factor (VEGF) promoter gene polymorphism in mastocytosis. A study of the European Competence Network on Mastocytosis (ECNM) (2008) (1)
Characterization and targeting of neoplastic stem cells in Ph+ chronic myeloid leukemia (2015) (1)
Recombinant Allergens: Basic Aspects and New Therapeutic Concepts (1995) (1)
Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial (2020) (1)
Diagnostic Criteria and Classification of Myelodysplastic Syndromes (2011) (1)
T cell receptor alpha mRNA transcription in T-lymphoblastic transformation of chronic myelocytic leukemia. (1988) (1)
N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia (2023) (1)
Comparative in vitro and in vivo studies with four radiolabelled somatostatin analogues in patients with endocrine tumours (1995) (0)
Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic Algorithm. (2022) (0)
cFinder: definition and quantification of multiple haplotypes in a mixed sample (2015) (0)
SETD2 Non-Genomic Loss of Function and p53 Functional Inactivation in Advanced Systemic Mastocytosis (SM): Pathogenetic and Therapeutic Implications (2017) (0)
Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis. (2023) (0)
Preface (2002) (0)
Overexpression of primary microRNA 221/222 in acute myeloid leukemia (2013) (0)
The Austrian Competence Network on Mastocytosis (AUCNM): a partner and part of the European ECNM network  (2013) (0)
New insights into the pathogenesis of the hyperimmunoglobulinaemia E syndrome (2005) (0)
Cytogenetic classification according to IPSS/-R is possible from peripheral blood in patients with Myelodysplastic Syndromes (2016) (0)
S113 GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA (2019) (0)
Su.123. Hom S 4, An Ige-Reactive Autoantigen Belonging to a Novel Subfamily of Calcium-Binding Proteins Can Induce Th1-Mediated Autoreactivity (2006) (0)
Normal ABL 1 is a Tumor Suppressor and Therapeutic Target in Human and Mouse Leukemias Expressing Oncogenic ABL 1 kinases Short title : ABL 1 is a tumor suppressor and therapeutic target (2016) (0)
Efficacy of standard treatment in patients with Hodgkin's disease--a single center experience. (2000) (0)
246 Epigenetic promoter-methylation regulates mRNA expression of apoptosis-mediators in MDS (2011) (0)
Nilotinib-induced vasculopathy : identification of vascular 1 endothelial cells as a primary target site 2 3 4 (2017) (0)
P098 Diagnostic and prognostic significance of tryptase in clinical hematology: evaluation of 1041 patients (2007) (0)
Prognostic Impact of Monosomy 7 as a Single Anomaly In Primary MDS – Reclassification From Poor to Intermediate Prognosis (2010) (0)
Identification of Basophils as Source of Hepatocyte Growth Factor (HGF) In CML: a Potential Trigger of Disease Acceleration. (2010) (0)
Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes (2023) (0)
P007 Attempts to define a No Risk subgroup in MDS by examining relative survival in well known scoring systems (2009) (0)
[The use of highly polymorphic DNA systems in the demonstration of mixed chimerism following bone marrow transplantation]. (1991) (0)
The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells. (2006) (0)
Targets and targeted drugs in chronic myeloid leukemia (2008) (0)
Hydroxyurea Induces Growth Inhibition in BCR-ABL1 T315I+ Clones and Synergizes with Ponatinib in Killing TKI-Resistant CML Cells (2016) (0)
ADCP Discharge Measurements on the River Danube: Post-Processing and Correction of Data (2019) (0)
Culen M Borsky M Oncotarget supplement (2016) (0)
IL-4 RECEPTOR ON BASOPHILS 1735 Histamine release from CGL basophils (2003) (0)
Abstract 424: Interference with alphaVbeta3 integrins via cyclic RGD peptides affects breast cancer cell behavior (2011) (0)
Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates with reduced allergenic activity (2019) (0)
Phenotyping of Neoplastic (CD34+/CD38−/CD123+) Stem Cells in Myeloid Malignancies Reveals Expression of Multiple Molecular Targets. (2005) (0)
318 A novel score optimized for accurate prediction of survival in patients with de novo myelodysplastic syndromes (2011) (0)
Abstract 5304: A serum protein test for improved prognostic stratification of patients with myelodysplastic syndrome (MDS) (2015) (0)
Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis (2016) (0)
Mutational Complexity Is Related To Disease Severity In Systemic Mastocytosis (2013) (0)
Estimating Rainfall Erosivity Factor Using Future Climate Projection in the Myjava Region (Slovakia) (2021) (0)
and association with PI3-kinase in myeloid leukemias Constitutive activation of Stat5 promotes its cytoplasmic localization (2008) (0)
The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition. (2007) (0)
Detection of Activated STAT5 in the Cytoplasm of Neoplastic Cells in Patients with AML, CML, and Systemic Mastocytosis. (2006) (0)
Age at disease onset has a major impact on clinical characteristics and course of mastocytosis (2017) (0)
Cross-Sensitization to Profilin ofPollen Profilin , Phl p 12 , for the Treatment GrassTail-to-Head Restructuring of Timothy A Hypoallergenic Vaccine Obtained (2007) (0)
A Phl p 7-specific IgG4 antibody inhibits allergic patients IgE cross-reactivity to allergens from the EF-hand family: importance of affinity and degree of cross-reactivity (2014) (0)
Aggressive Systemic Mastocytosis: A review (2014) (0)
Dust Mite Allergen , into a Hypoallergenic Conversion of Der p 23 , a New Major House and (2014) (0)
Predicting long-term catchment nutrient export: the use of nonlinear time series models (2010) (0)
Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis (2013) (0)
C013 The influence of therapeutic strategies on survival in distinct cytogenetic subgroups – A collaborative study based on 3860 patients with MDS (2007) (0)
Identification of Oncostatin M as a Novel KIT D816V-Dependent Cytokine in Neoplastic Human Mast Cells. (2009) (0)
Dissecting GATA1 Protein Interactions in Normal and Malignant Human Erythroblasts (2021) (0)
Biology, phenotype and target expression profiles of neoplastic stem cells in myeloid leukemias (2013) (0)
Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells (2020) (0)
ID: 66: Targeting STAT5 in Hematopoietic Malignancies (2015) (0)
Poster: MPN-435 Overall Survival in PatientsWith Systemic Mastocytosis With Associated Hematologic Neoplasm Treated With Avapritinib Versus Best Available Therapy (2022) (0)
CONSENSUS DOCUMENT ICON : Eosinophil Disorders (0)
Affinity for IgE Single-Chain Antibody Fragment with High RI, and a Recombinant Nonanaphylactic e Trimolecular Complex Formation of IgE, Fc (0)
Low-Level Expression of the Tumor Suppressor Bim in CML Cells: Role of BCR/ABL, Delineation of Underlying Signaling Pathways, and Re-Expression by Imatinib, AMN107, and Proteasome Inhibitors. (2005) (0)
Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors (2015) (0)
Subject Index Vol. 133, 2004 (2004) (0)
CEBPA-Mutant Acute Myeloid Leukemia is Sensitive to Small-Molecule-Mediated Inhibition of the Menin-MLL Interaction (2018) (0)
Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS (2022) (0)
Abstract A5: Characterization of signaling pathways related to resistance of breast cancer cells against irreversible EGFR/HER/ErbB kinase inhibitors (2010) (0)
Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories (2022) (0)
cell-mediated tumor surveillance Leukemic challenge unmasks a requirement for PI3K{delta} in NK (2009) (0)
Targeted genes in haematology (2004) (0)
recombinant human interleukin-6 on thrombopoiesis in primates In vivo synergism of recombinant human interleukin-3 and (2011) (0)
transplantation hematopoietic stem cells after allogeneic bone marrow Origin of human mast cells: development from transplanted (2011) (0)
Cancer - A devastating disease, but also an eye-opener and window into the deep mysteries of life and its origins. (2022) (0)
Abstract 3957: Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene (2015) (0)
In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors (2019) (0)
Phenotypic characterization of disease‐initiating stem cells in JAK2‐ or CALR‐mutated myeloproliferative neoplasms (2023) (0)
IMMUNOTHERAPYI (1997) (0)
S888 TNF-ALPHA PROMOTES CLONAL EXPANSION OF KIT D816V+ CELLS IN SYSTEMIC MASTOCYTOSIS (2019) (0)
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies (2022) (0)
The Serum Tryptase Test: Use in Clinical Hematology (2020) (0)
Management of Chronic Myeloid Leukemia with BCR/ABL Inhibitors: Current Status and Future Perspectives (2010) (0)
Impact of HFE gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes. (2019) (0)
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis. (2022) (0)
[Interleukin-3: a preclinical study]. (1989) (0)
Dielectric Properties and Breakdown of the Gate Oxide in the MOS Structure (2010) (0)
myelofibrosis hypertension due to extramedullary hematopoiesis in idiopathic Transjugular intrahepatic portosystemic shunt for treatment of portal (2011) (0)
P018 Host related features explain heterogeneity in risk groups of disease related scoring systems in MDS (2009) (0)
137 Standardization of flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group (2011) (0)
Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL). (2008) (0)
Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML (2015) (0)
The value of satellite soil moisture and snow cover data for the transfer of hydrological model parameters to ungauged sites (2021) (0)
295 IDIOPATHIC CYTOPENIA OF UNKNOWN SIGNIFICANCE (ICUS) AND IDIOPATHIC DYSPLASIA OF UNKNOWN SIGNIFICANCE (IDUS): A MULTI-CENTER REGISTRY STUDY (2015) (0)
Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS (2018) (0)
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives. (2023) (0)
Establishment of a Novel Canine Mastocytoma Cell Line, NI-1: a Model for Studying Resistance Against KIT Tyrosine Kinase Inhibitors In Canine Neoplastic Mast Cells (2010) (0)
Diagnosis and Therapy of Fish Allergy Cross-Reactive Fish Allergen : A Tool for Recombinant Carp Parvalbumin , the Major Valenta and Susanne Spitzauer (2002) (0)
119 2011-update and overview of data in the German-Austrian-Suisse MDS registry (D-A-CH MDS registry) (2011) (0)
106 Mast cell (MC) lineage involvement in myelo-dysplastic syndromes: Diagnostic utility of tryptase staining (1997) (0)
Expression of Interleukin Receptors on Human Eosinophils, Basophils, and Mast Cells (1990) (0)
Nilotinib and Dasatinib Produce Synergistic Growth-Inhibitory Effects In Imatinib-Resistant CML Cells, Including Subclones Bearing the Multi-Resistant BCR/ABL Mutant T315I (2010) (0)
Low cost precipitation measurement in remote areas (2020) (0)
PPM1D Mutations in MDS Patients with Deletion of Chromosome 5q (2017) (0)
Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis. (2006) (0)
Abstract B01: Multilevel interference with receptor-PI3K-mTORC1 signaling is key mechanism for anticancer activity of fatty acid synthase inhibitors (2016) (0)
Cooperative Anti-Leukemic Effects of Imatinib and Mcl-1 Antisense: Identification of Mcl-1 as a Novel Target in CML. (2004) (0)
CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells (2022) (0)
The Target Receptor Siglec-3 (CD33) Is Expressed on AML Stem Cells in a Majority of All Patients with AML. (2005) (0)
Imatinib Inhibits SCF-Induced Development Of Human Mast Cells In Vitro and Induces Profound and Selective Mast Cell Deficiency In Patients With Ph+ CML (2013) (0)
Nilotinib exerts proatherogenic and growth-inhibitory effects on endothelial cells: a potential mechanism underlying drug-related vasculopathy in Ph plus CML (2014) (0)
Spectrum, Function, and Value of Targets Expressed in Neoplastic Mast Cells (2009) (0)
Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both? (2017) (0)
Bradyarrhythmias Associated with Sofosbuvir Treatment (2015) (0)
Interleukin 8 gene polymorphism in mastocytosis. A study of the European Competence Network on Mastocytosis (ECNM) (2008) (0)
P110 Individualized IPSS in MDS by considering age, gender and FAB – a multicenter analysis (2007) (0)
P022 Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes (2009) (0)
55. 123I-epidermal growth factor receptor monoclonal antibody: preparation and in vitro studies in human breast cancer (1992) (0)
ImmunogenicityAllergenic Activity and Preserve Grass Pollen Allergen, Phl p 6, to Reduce Genetic Engineering of the Major Timothy (2007) (0)
PhD Program Malignant Diseases (2009) (0)
Contents Vol. 133, 2004 (2004) (0)
Investigation of the seafloor preconsolidation foundation concept. Report : Refs. Naval Civ. Engng. Lab. Port Hueneme, Calif. USA, May, 1973, 28P (1974) (0)
Proliferation Kinetics of Subclones Carrying Point Mutations In the BCR-ABL TKD During TKI Treatment In CML Patients: Quantitative Monitoring by LD-PCR (2010) (0)
DNA polymerase theta protects leukemia cells from metabolic-induced DNA damage. (2022) (0)
MYELOID NEOPLASIA Identi ﬁ cation of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis (2015) (0)
Proposed International Prognostic Scoring System for Mastocytosis (IPSM) (2019) (0)
progenitors genomic instability in chronic myeloid leukemia stem cells and primitive mitochondrial respiratory chain complex III-generated ROS cause - Rac2 (2012) (0)
Functional Analysis of the CML Blast Crisis Transcriptome and Epigenome Using Crispr-CAS9 and Pharmacologic Approaches (2015) (0)
PP-3: Urinary-type plasminogen activator (uPA) receptor expression on human tumour cells (1997) (0)
Mastocytosis—c‐Kit Mutations (2004) (0)
Subject Index Vol. 127, 2002 (2002) (0)
Hypoallergenic polypeptides hybrids for treating allergy (2010) (0)
Splenomegaly and elevated alkaline phosphatase are strong and independent adverse prognostic markers in patients with systemic mastocytosis (2016) (0)
Assessment of the role of basophils in promoting allergen-specific T-cell proliferation in allergic patients (163.3) (2011) (0)
Histamine Monitoring in Patients with CML during Treatment with Imatinib: Comparison to Monitoring by Cytogenetics and BCR/ABL. (2005) (0)
Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56bright NK Cells in Acute Myeloid Leukemia (2014) (0)
Contents Vol. 79, 2007 (2007) (0)
5. DIFFERENTIATION OF HUMAN BASOPHILS AND HUMAN MAST CELLS) (1993) (0)
S840 IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA – A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP (2019) (0)
Contents Vol. 33 (2003) (0)
KIT D816 Mutated / CBF-Negative Acute Myeloid Leukemia (AML): A New Poor-Risk Subtype Associated with Systemic Mastocytosis (SM-AML) (2018) (0)
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT 3 ( ITD )-positive leukemia cells to PARP 1 inhibitors Short title : FLT 3 and PARP 1 inhibitors against AMLs (2018) (0)
Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders. (2004) (0)
Delineation of Predictive Features of AML Patients with Recurrent Relapse Who Achieved Repeated Complete Remission after Multiple Re-Induction and Consolidation Therapies (2022) (0)
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted (2023) (0)
5-Azacytidine and Decitabine Induce FAS Re-Expression, Exert Major Proapoptotic Effects, and Cooperate with the FAS Ligand in Producing Apoptosis in Neoplastic Human Mast Cells, (2011) (0)
Clofarabine/Cyclophosphamide (ClofCy) for Debulking refractory Acute Leukemias Prior to Allogeneic Hematopoietic Stem Cell Transplantation (2012) (0)
Prognostic Factors Predicting Survival in De Novo AML Patients Requiring Intensive Care. (2007) (0)
P119 The integration of comorbidity in decision making in myelodysplastic syndromes (2007) (0)
Contents, Vol. 99, 1992 (1992) (0)
O-33 Cryogenetic profile in 2124 patientswith MDS — Correlations with morphology, clinical course and prognosis (2005) (0)
DomainCharacterization of the Epitope-Containing Molecular, Immunological, and Structural Timothy Grass Pollen Allergen, Phl p 5: a Highly Allergenic Fragment of the Major A Human Monoclonal IgE Antibody Defines (2000) (0)
KIT D816V tissue mutation burden is a new biomarker and independent predictor of survival in mastocytosis (2019) (0)
as a Mosaic Protein Grass Pollen Allergen Phl p 2 by Reassembly Disruption of Allergenic Activity of the Major (2008) (0)
MYELOID NEOPLASIA A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D 816 V transfection (2014) (0)
Differentiation Antigens Synthesis, and Early Mast Cell Induction of Cluster Formation, Histamine Unique Effects of KIT D816V in BaF3 Cells: (2008) (0)
MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity (2018) (0)
The somatostatin receptor subtype 3 acts as an acceptor of vasoactive intestinal peptide (1998) (0)
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues (2022) (0)
P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS (2022) (0)
Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells (2008) (0)
PS1437 SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS (2019) (0)
ANALYSIS OF THE PERCENTAGE OF PATIENTS REQUIRING INTENSIVE CARE IN 406 CONSECUTIVE PATIENTS WITH DE NOVO AML.: 128-M (2005) (0)
[New concepts in therapy of type I allergic diseases]. (1993) (0)
Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia (2020) (0)
ESCI Announcement (2012) (0)
Liposomal Cytarabine (DepoCyte) for Treatment of Myeloid CNS Relapse in CML Occurring during Therapy with Imatinib. (2007) (0)
Multidisciplinary Management of Mastocytosis Broesby-Olsen , Sigurd 2016-07 (0)
Characteristics and process controls of statistical flood moments in Europe – a data based analysis (2020) (0)
PS1331 MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL (2019) (0)
BCR/ABL Induces Expression of Histidine Decarboxylase and Synthesis of Histamine in CML Cells. (2005) (0)
79 Antigenic characterization of bone marrow endosteal cells: A stem cell hypothesis reevaluated (1997) (0)
ACTUAL IMPLANTATION AND MONITORING PROGRAME OF LOW TEMPERATURE SOLAR HEATING INSTALLATIONS IN CATALUNYA (SPAIN) (1986) (0)
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology (2015) (0)
A Polymorphism Study on Detoxification and DNA Repair Genes in 700 MDS Patients Demonstrates An Association Between Genotype and An Aberrant Karyotype (2008) (0)
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes (2021) (0)
Expression of VIP and somatostatin receptors on human breast cancer cells (1995) (0)
Subject Index Vol. 126, 2001 (2001) (0)
From Molecular Science to the Treatment of Allergy (1999) (0)
269 Molecular interplay between cancer cell fatty acid metabolism and oncogenic signaling as resource for novel treatment strategies against ovarian cancer (2015) (0)
Chemotherapy on Days 1 , 3 , and 5 Pulse Cytosine Arabinoside-Consolidation Granulocytes in Leukemic Patients Receiving Antibacterial Function of Persisting Immunological Characterization and Valent (2006) (0)
THROMBIN INDUCED MAST CELL CHEMOTAXIS MIGHT PLAY AN ESSENTIAL ROLE IN THROMBOSIS (1999) (0)
Classification and response criteria in mastocytosis: is there a need to revise? (2010) (0)
Pro-Atherogenic and Anti-Angiogenic Effects of Nilotinib on Endothelial Cells: A Potential Mechanism to Explain Vasculopathies in Cml Patients Treated With Nilotinib (2014) (0)
Rainfall-runoff simulation methods for extreme flood estimation – Application to Gardons catchments (2014) (0)
A low-cost 3D printed system for monitoring meteorological characteristics in citizen-science projects (2018) (0)
240 DYSPLASIAS REVISITED – CONSIDERATIONS FOR A MULTIDIMENSIONAL APPROACH TO HETEROGENEITY OF MDS: DATA ON 1979 PATIENTS FROM THE GERMAN AUSTRIAN DATA BASE (2015) (0)
Incidence and prognostic impact of cytogenetic aberrations in systemic mastocytosis (2016) (0)
Next Generation Sequencing Identifies DNA Methylation Patterns Indicative of Disease Progression in Ph+ CML (2014) (0)
Mastocytosisof the Hematopoietic Stem Cell (2008) (0)
PO-7: 123I-vascular endothelial growth factor (VEGF)-165 (1997) (0)
Glucocorticosteroids rescue basophils from dasatinib-1 augmented IgE-mediated histamine release 2 (2015) (0)
On the safety of low-dose dasatinib in comorbid and non-comorbid patients: what is real-life? (Reply) (2011) (0)
Ndel1-Pdgfrb Fusion Gene In Juvenile Myelomonocytic Leukemia Associated With Resistance To Tyrosine Kinase Inhibitors (2015) (0)
QuantitationofMinimal Residual Disease in AcuteMyeloid Leukemia by TryptaseMonitoring Identifies a Group of Patientswith a High Riskof Relapse (2005) (0)
Characterization of prostaglandin binding receptors expressed on human endothelial cells (1995) (0)
Antineoplastic efficacy profiles of avapritinib and nintedanib in KIT D816V+ systemic mastocytosis: a preclinical study. (2023) (0)
Chapter 71 – Eosinophilia, Eosinophil-Associated Diseases, Eosinophilic Leukemias, and the Hypereosinophilic Syndromes (2018) (0)
Contemporary Diagnosis and Management of Systemic Mastocytosis (2007) (0)
O-023 Did the prognosis of MDS patients improve during the last 30 years? (2013) (0)
The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Clinical Experiences, Co-Morbidities and Additional Concerns (2015) (0)
Rapid Identification Of Compound Mutations In Patients With Ph-Positive Leukemias By Long-Range Next Generation Sequencing (2013) (0)
Expression of the CAMPATH-1 Antigen (CD52) on CD34+/CD38- Progenitor Cells in Patients with 5q- MDS and in a Subset of AML (2011) (0)
A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting (2020) (0)
Molecular Quantification of Tissue Mast Cell Burden in Systemic Mastocytosis: A New Approach for Diagnostics and Prognostication (2018) (0)
Phenotyping of human basophils and mast cells (1994) (0)
Polo-like kinase-1 ( Plk1 ) as a novel drug target in canine and human neoplastic mast cells (2011) (0)
Similarities of exogenous and endogenous allergens; IgE-autoreactivity in atopic patients (1993) (0)
Isolation and Culture of Mast Cells and Basophils (2002) (0)
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes. (2019) (0)
P-10 Influence of age and gender on survival in MDS: Importance of an IPSS*gender interaction — A multicenter analysis on 1159 patients (2005) (0)
Pan-AllergenNovel Cross-Reactive Invertebrate , a Plodia interpunctella Indianmeal Moth, Characterization of Arginine Kinase from the Molecular and Immunological (2001) (0)
Abstracts of the Second International Symposium: Cytokines in hemopoiesis, oncology and aids (2005) (0)
Submicronic Respirable Particles Marker Allergens : Expulsion from Pollen via Polygalacturonases as Grass Pollen-Specific Molecular Characterization of (2004) (0)
High Affinity for IgE with Single-Chain Antibody Fragment Recombinant Nonanaphylactic IgE, Fc{epsilon}RI, and a Trimolecular Complex Formation of (2010) (0)
Paul Ehrlich (1854-1915) and the Birth of Molecular Medicine (2015) (0)
Cover Image, Volume 16, Issue 1 (2018) (0)
Preview : Published ahead of advance online publication Drug-induced inhibition of phosphorylation of STAT 5 overrides drug resistance in neoplastic mast cells (2017) (0)
Reply to "Need to define a subgroup of patients with idiopathic mast cell activation syndrome". (2022) (0)
Degranulation Interaction and Allergen-Induced Basophil Human IgE and Inhibit the Human IgE-Allergen Antibodies That Recognize Similar Epitopes as Recombinant Allergens Induces Mouse IgG 1 Immunization with Purified Natural and (1998) (0)
Mastocytosis and Mast Cells (2010) (0)
Abstract 13269: The Tyrosine Kinase Inhibitor Nilotinib Induces Vascular Adverse Events in Patients With Chronic Myeloid Leukemia and Inhibits Endothelial Function and Angiogenesis (2013) (0)
Identification of Campath-1 Antigen (CD52) As a Novel Therapeutic Target in Advanced Systemic Mastocytosis. (2012) (0)
Contents Vol. 122, 2000 (2000) (0)
Subject Index Vol. 122, 2000 (2000) (0)
Abstract 1184: Characterization of novel STAT5 inhibitors to interfere with the oncogenic activities of STAT5 in hematopoietic diseases (2017) (0)
P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY (2022) (0)
The Mastocytosis Society Survey On Mast Cell Disorders: Patient Experiences and Perceptions (2013) (0)
Revealing the pathogenesis of the 5q‐ syndrome (2008) (0)
Allogeneic Stem Cell Transplantation Cells from the Leukemic Clone and Eradication by Myelomastocytic Leukemia : Evidence for the Origin of Mast (2005) (0)
Interleukin-4 Downregulates Expression of c-kit mRNA and YB5.B8 Antigen (Stem Cell Factor Receptor) in Human Myeloid/Mast Cell Progenitor Cells (1992) (0)
Genomic landscape in KIT D816V+ advanced systemic mastocytosis (2015) (0)
20 – Systemic mastocytosis* (2012) (0)
Contents Vol. 157, 2012 (2012) (0)
Prognostic signiﬁcance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes (2008) (0)
Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders (2021) (0)
Mastocytosis: Overview of Diagnosis and Classification (2019) (0)
Contents Vol. 126, 2001 (2001) (0)
The Heat Shock Protein 32 (Hsp32)/HO-1-Targeting Drug SMA-ZnPP and the Triterpenoid CDDO-Me Exert Synergistic Growth-Inhibitory Effects on TKI-Resistant Leukemic Cells in Ph+ CML (2011) (0)
A “tail-to-head” - derivative from timothy grass pollen profilin (2004) (0)
80 Phenotypic analysis of endosteal cells in myelodysplastic syndromes and other hemopoietic disorders (1997) (0)
History and Current Status of Mastocytosis Research in the European Competence Network on Mastocytosis (2019) (0)
mast cells and basophils C5a stimulates production of plasminogen activator inhibitor-1 in human (2013) (0)
Investigation of the seafloor preconsolidating foundation concept. / by P.J. Valent, D.A. Raecke, and H.G. Herrmann. (1973) (0)
P103 Prognostic significance of LDH as a dynamic variable in myelodysplastic syndromes (2007) (0)
Vitamin D supports the efficiency of decitabine for induction of differentiation, apoptosis and osteocalcin expression in leukemia and mastocytosis (2012) (0)
P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY (2022) (0)
Impact of allergic disorders and anaphylaxis in mastocytosis: Preliminary data from a study of the European Competence Network on Mastocytosis (ECNM) registry (2017) (0)
Role of Basophils in Allergic Reactions (1998) (0)
Cell Type 1-Mediated Autoreactivity Calcium-Binding Proteins , Can Induce Th Belonging to a New Subfamily of Hom s 4 , an IgE-Reactive Autoantigen (2005) (0)
Evaluation of the effects of the PKC412-metabolites CGP52421 and CGP62221 on proliferation and viability of neoplastic mast cells and IgE dependent secretion of histamine (2013) (0)
Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph+ Chronic Myeloid Leukemia (2022) (0)
Deciphering the Mechanisms of Osteoblast-Induced Resistance of Leukemic Stem Cell (LSC) in Ph+ CML: Role of PI3-Kinase, BRD4 and MYC and Development of Strategies to Overcome Osteoblast-Induced Resistance (2021) (0)
Pollen Phleum pratense Timothy Grass ( and P-Particle-Associated Protein from AllergenCharacterization of Phl p 6 , a Major Molecular , Immunological , and Structural (1999) (0)
Contents Vol. 127, 2002 (2002) (0)
The Multi-Kinase/ABL Inhibitor R763/AS703569 Induces DNA Endoreduplication and Apoptosis In Imatinib-Resistant CML Cells and Synergizes with Nilotinib, Dasatinib, and the Plk-1 Inhibitor BI 2536, In Producing Growth Inhibition. (2010) (0)
Continuous Simulation of Catchment Runoff in Flood Frequency Analysis: A Case Study from Slovakia (2018) (0)
Digital Droplet PCR: Next Generation KIT D816V Testing As Advanced Tool for Diagnosis and Prognostication in Mastocytosis (2017) (0)
Impact of RAS-Pathway Activation on Phenotype and Outcome in Patients with Chronic Myelomonocytic Leukemia and a TET2/SRSF2 Comutation (2021) (0)
Recombinant allergen, its fragments and its corresponding DNA molecules, vectors, and hosts containing these DNA molecules and dignostische and therapeutic uses of said allergens and fragments (1995) (0)
Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis. (2022) (0)
Subject Index Vol. 79, 2007 (2007) (0)
P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE (2022) (0)
Allergens of house dust mites. (2004) (0)
154 Some determinants of disease specific mortality in MDS (2011) (0)
Mast cell increase and redistribution in auricular thrombosis (1994) (0)
Diagnostic and Prognostic Significance of Tryptase in Clinical Hematology: A Single Center Experience from 1070 Patients. (2006) (0)
P028 Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q) (2009) (0)
PARP1 Inhibitors Eliminated Imatinib-Refractory Chronic Myeloid Leukemia Cells in Bone Marrow Microenvironment Conditions (2018) (0)
Allergen, Bet v 1 to a Surface Patch on the Major Birch Pollen Simultaneous Binding of Different IgE Antibodies Peptide-Specific Monoclonal Antibodies Reveals Mapping of Conformational IgE Epitopes with (2011) (0)
Calcium-Binding Allergen , Phl p 7 Structure of the Cross-Reactive Disruption of the Three-Dimensional Generation of an Allergy Vaccine by Rudolf Valenta (2004) (0)
Investigation of the seafloor preconsolidating foundation concept. (1973) (0)
Major Birch Pollen Allergen, Bet v 1 IgE Antibodies to a Surface Patch on the Reveals Simultaneous Binding of Different with Peptide-Specific Monoclonal Antibodies Mapping of Conformational IgE Epitopes (2011) (0)
Reaction of wood radius of multiple tree species to changing environmental conditions (2017) (0)
P006 Idiopathic cytopenia of uncertain significance (ICUS) versus low risk MDS: the diagnostic interface (2007) (0)
Prognostic Significance of Serial Determinations of LDH Levels in Primary (De Novo) Myelodysplastic Syndromes. (2006) (0)
Clinical Course and Prognosis in Mast Cell Proliferative Disorders: A 17 Year Experience in a Single Center. (2004) (0)
F3AK treatment of aggressive lymphoma cells results in induction of apoptosis in vitro (2022) (0)
Abstracts presented at the ESVONC Annual Congress, Turin, Italy, 18-20 March 2010. (2011) (0)
CCL-2 Is a KIT D816V-Dependent Modulator of Bone Marrow Remodeling and Microenvironmental Alterations in Systemic Mastocytosis (2015) (0)
O.12 The relevance of comorbidities in myelodysplastic syndromes (2007) (0)
Alternative Approaches to a Calibration of Rainfall- Runoff Models for a Flood Frequency Analysis (2014) (0)
Cross-Competition Between Vasoactive Intestinal Peptide (VIP) and Somatostatin (SST) for Binding to Specific Receptors Expressed on Endothelial Cells, Basophils, Mast Cells and Monocytes: Pathophysiology and Clinical Implications (1996) (0)
Differential expression of complement (C−) AGs on human basophils, skin mast cells and other mast cell subsets (1994) (0)
University of Southern Denmark Multidisciplinary Management of Mastocytosis (2016) (0)

This paper list is powered by the following services:

Other Resources About Peter Valent

en.wikipedia.org

What Schools Are Affiliated With Peter Valent?

Peter Valent is affiliated with the following schools:

Peter Valent's Academic­Influence.com Rankings